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 Acute Myeloid Leukaemia (AML) is a cancer of hematopoietic stem cells that develops 
in the three-dimensional (3-D) niches provided by the bone marrow microenvironment in 
vivo. The study of AML has been hampered by the lack of appropriate ex vivo models, which 
can mimic this microenvironment. It was hypothesised that the fabrication of scaffolds for the 
biomimetic growth of leukemic cells ex vivo could facilitate the study of the disease in its 
native 3-D niche. The growth of different leukemic cell lines was first evaluated, namely K-
562, HL-60 and Kasumi-6 on highly porous scaffolds fabricated from biodegradable and 
non-biodegradable polymeric materials:  poly (L-lactic-co-glycolic acid) (PLGA), 
polyurethane (PU), poly (methyl-methacrylate) (PMMA), poly (D, L-lactade) (PDLLA), poly 
(caprolactone) (PCL), and polystyrene (PS). These results were compared with two 
commercially available scaffolds from BD™ Biosciences. Overall, out of all the scaffolds, 
PLGA and PU displayed the best seeding efficiency and leukemic cellular growth, assessed 
by MTS assay, scanning electron microscopy and immunohistochemistry. In order to 
improve the ex vivo 3-D leukemic cell culture, PLGA and PU scaffolds were coated with 
bone marrow extracellular matrix (ECM) proteins, collagen (62.5 or 125 µg/ml) and 
fibronectin (25 or 50 µg/ml) and a combination of both proteins: collagen + fibronectin (62.5 
+ 25 µg/ml) respectively. Once the abnormal hematopoietic 3-D model was established, a 
new model to culture normal hematopoietic cord blood mononuclear cells was studied and 
compared. All 3 leukemic cell lines and cord blood cells grew better in PU scaffolds coated 
with collagen type I using the low concentration and sustained growth in the absence of 
exogenous cytokines. As a result, it was concluded that PU-collagen scaffold could provide a 
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practical model with which to study the biology and treatment of primary AML in an ex vivo 
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The production of billions of new blood cells each day is carried out by the stem cells of 
the bone marrow and is called hematopoiesis; the blood cell production rate of a healthy adult 
is around 3 million red cells and 120,000 white cells every second 1. Researchers have spent 
years trying to identify and characterise them but it has been a difficult challenge since they 
look and behave in culture like ordinary white blood cells. However, there are two properties 
that make stem cells unique, firstly the self renewal capacity, which allows the maintenance 
of the undifferentiated stem cell pool over a period of time, and secondly the ability to 
differentiate to a variety of specialised cells 2. Their molecular signature divides the stem 
cells in three different classes: embryonic stem cells (ES), hematopoietic stem cells (HSC) 
and neural stem cells (NSC) 3.  
In this thesis I have focused my investigation in the study of one particular class: the 
hematopoietic stem cells. Hematopoiesis is regulated in the bone marrow, a complex 3-D 
tissue composed  by a heterogeneous population of hematopoietic and nonhematopoietic 
stromal cells 4. The hematopoietic stem cells and their microenvironment (HM) are unique 
and perform several tasks that no other cells can achieve. They are indefinitely housed in the 
bone marrow in spaces called niches which control their properties, support HSCs self-
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renewal and prevent them from differentiating. Therefore the dysregulation of the niches, 
either in structure or function, results in the pathogenesis of disease states of the bone 
marrow, such as leukemia which was studied in detail in this thesis. The different types of 
leukemia are grouped by the cell affected, myeloid or lymphoid, and by the rate of the cell 
growth, acute or chronic. 
• Acute leukemia involves an overgrowth of very immature blood cells. This 
condition is life-threatening because there are not enough mature blood cells to 
prevent anemia, infection and bleeding. A diagnosis of acute leukemia is made when 
there are 20 percent or more blasts or immature cells in the bone marrow 5. 
• Myelodysplastic Syndrome (MDS) is a condition in which the bone marrow does 
not function normally and therefore does not produce enough normal blood cells. The 
blood cells affected are white blood cells, red blood cells and platelets. Some cases of 
MDS may, over time, progress to acute leukemia 6. 
• Chronic leukemia involves an overgrowth of mature blood cells. Usually, people 
with chronic leukemia have enough mature blood cells to prevent serious bleeding 
and infection 7. 
The necessity of identifying the pathways and stimulus involved in the self-renewal and 
differentiation processes of both, normal and leukemic stem cells, is required in order to 
understand the events that lead to the development of cancer, but at the moment it is 
unknown which are the abnormalities required for leukemic transformation. The study of the 
process of normal hematopoiesis and leukemogenesis has been limited by the lack of three 
dimensional growth environment, which is not supported by 2-D culture. Therefore it was 
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hypothised that by using an ex vivo 3-D culture system, cellular growth could be maintained 
and the disease could be better understood. The 3-D culture system was designed in the form 
of a scaffold made of a synthetic polymer. 
As a result, and to study the indicated problem and elucidate an answer, this thesis was 
produced and the result is here presented. The specific scientific objectives for this thesis are 
summarised in table 1.1:  
Table 1.1 Scientific objectives for chapters 5, 6, 7 and 8. 
Chapter Scientific objectives 
Chapter 5 Scaffold Fabrication and Characterisation 
Chapter 6 Scaffold Evaluation 
Chapter 7 Optimisation of Scaffolds 
Chapter 8 Generation of normal 3-D ex vivo hematopoiesis mimicry 
 
 In Chapter 2, a review of current research and background is presented and is separated 
into two main sections: normal hematopoietic stem cells and their bone marrow 
microenvironment; and acute myeloid leukemia. Chapter 3 introduces the aims and 
objectives together with the hypothesis generated at the beginning of the study. Materials and 
methodologies used in the investigation are presented in Chapter 4, which includes the 
technique of protein coating for scaffold optimisation. In Chapter 5, the six polymers initially 
selected are introduced, together with two commercially available scaffolds, and fabrication 
and characterisation methods to produce them are detailed. Chapter 6 offers the comparison 
of the 6 polymeric scaffolds seeded with AML cell lines, and the results of the most suitable 
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biodegradable and non-biodegradable polymers are presented. Scaffold optimisation of the 
two selected scaffolds is described in Chapter 7, and Chapter 8 includes the validation of the 
3-D culture system using cord blood cells and the expansion of mononuclear cells without the 
addition of exogenous cytokines. Finally, the main conclusions of the thesis are drawn in 


























2.1  HAEMATOPOIESIS AND BONE MARROW MICROENVIRONMENT 
 Hematopoiesis is the production of new blood cells, which, in healthy adults, takes place 
in the bone marrow 8. The bone marrow (BM) is a complex three-dimensional tissue where 
hematopoiesis is regulated by spatially arranged cellular microenvironments (niches). The 
BM is composed of a heterogeneous population of hematopoietic and non-hematopoietic 
stromal cells such as endothelial cells, adipocytes or macrophages, their extracellular matrix 
products, and cytokines 4. Even though BM is the classic source of hematopoietic stem cells 
(HSC) for transplantation, two other sources are being used for clinical transplantations: 
peripheral blood (PB) and cord blood (CB) and will be covered in Chapter 8.  
 The HSCs of a healthy adult have two characteristics that render them unique: they can 
self-renew and differentiate into all blood cell lineages, such as erythrocytes, neutrophils, 
eosinophil, and basophils, granulocytes, mast cells, monocytes and macrophages, platelets, B 
lymphocytes, T lymphocytes, natural killer cells and dendritic cells 9. Depending on their self 
renewal capacity, HSCs can be divided in two groups: long-term stem cells (LT-HSC), which 
can restore the hematopoietic system in a period of several months and generate descendents 
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that display similar potentiality on secondary transplants, and short-term progenitor or 
precursor cells (ST-HSC), which in contrast can immediately regenerate all the blood cell 
types, alas under normal circumstances cannot renew themselves long term 8. LT-HSC 
produce ST-HSC, which give rise to lineage-committed progenitor (LCP) cells. LCP cells 
produce the over 10 different types blood cells 10.  
 HSCs may be identified through their clusters of differentiation (CD) used to classify 
cells into subsets.  For that reason, monoclonal antibodies directed against these surface 
proteins are used. The following markers have been proposed as the “best” HSCs markers for 
humans and mice by Weissman 11.  
HUMAN: CD34+, CD59+, Thy1+, CD38low/- 
MOUSE: CD34low/-, SCA-1+, Thy1+/low, CD38+ 
In order to identify HSCs, the CD34 marker is the one normally used. CD34 is expressed 
on 0.5-5% of early progenitor BM cells but not in their mature descendents. It is a cell 
surface glycoprotein and functions as a cell-cell adhesion factor; it also mediates the 
attachment of stem cells to BM ECM or directly to stromal cells 12. In addition, selection of 
CD34+ cells is often beneficial in reducing tumor cell appearance because many cancerous 
cells lack this antigen 13. Hao, Q. et al (2001) identified surface markers, such as CD10 or 
CD7, on CD34+ which defined the earliest human lymphoid committed progenitor. In 
contrast, cell surface markers, such as IL-3Rαlo or CD45RA-, on CD34+CD38+ were found to 
give rise to all types of myeloid progenitor cells 14. Furthermore, isolation of HSCs has been 
performed using the above described cell surface markers and fluorescent dyes, such as 
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Hoechst 15 or PKH-26 16, which indicate cell proliferation status. However, expression of 
these proteins has proven not to be necessary for stem cell function and, therefore, might not 
be related to the stem cell potential. Consequently, the only universal assay used to identify 
HSCs is the use of lethally irradiated hosts, such as mice, to repopulate the host’s marrow.  
One set of important molecules that regulate hematopoiesis are the cytokines. Stimulatory 
and inhibitory cytokines control hematopoiesis that occurs in the intersinus spaces of the 
marrow. They are produced from the endothelium and reticular cells of the bone marrow 
stroma. Cytokines act on their target cells by binding to specific membrane receptors; the 
receptors can be divided into several families based on their structure and activity. These 
families are: hematopoietin, interferon, tumor necrosis factor, and chemokine families 17. 
 
2.1.1 Stem Cell Properties 
The stromal cells in the hematopoietic microenvironment (HM) of the bone marrow 
perform multiple tasks including the production of extracellular matrix (ECM) proteins and 
basal lamina collagens, including types, I, III, IV, V, and VI. Stromal cells also synthesise 
other matrix proteins, such as fibronectin, thrombospondin, hemonectin and laminin 18, and 
promote and regulate stem cell self-renewal, commitment, differentiation, and proliferation 
through their secreted extracellular matrix proteins and cytokine environment 19. Therefore, 
HM regulates the growth, differentiation and survival of HSCs through different mechanisms 




I. Interactions between hematopoietic cells and cytokines. 
II. Interactions between hematopoietic and stromal cells through cell adhesion 
molecules. 
III. Interactions between the hematopoietic cells adhesion molecules and the ligands on 
ECM components. 
The critical properties that make HSCs unique are the self renewal and differentiation 
capacity combined with their mobilisation and apoptosis attributes. 
 
2.1.1.1 Self-renewal and Differentiation 
HSCs evolve into more differentiated cells through a variety of committed progenitor 
cells; during this commitment process, mature cells are produced after undergoing extensive 
proliferation and sequential differentiation, together with a decrease in self-renewal capacity 
2. As a general rule, as differentiated characteristics are attained, the self-renewal potential 
declines precipitously 9. In culture, HSCs produce large increases in the number of progenitor 
cells that give rise to the different blood cell lineages; alas, they cannot renew themselves and 
the number of true stem cells is insignificant 10. Care must be taken when interpreting data on 
HSC self-renewal, since it is possible to generate cells that may still have properties within 
the stem cell compartment but are associated with commitment and do not represent self-
renewal 20. The ability of a stem cell to differentiate into various mature phenotypes is called 
potential or plasticity. In particular, there are small numbers of undifferentiated stem cells in 
the bone marrow that can give rise to nine different mature cell types 21, depending on the 
environment in which they exist.  A HSC undergoes between 17 to 19.5 divisions during the 
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course of producing a mature, circulating blood cell; that is a net amplification of between ~ 
170,000 and ~ 720,000 22. 
Figure 2.1 shows the hematopoietic system differentiation pathway. The direct offsprings 
of HSCs in adult bone marrow are known as multipotent progenitors (MPP), which are 
capable of differentiating into a variety of cells but lack the extensive self-renewal capacity 
of HSCs. When MPP differentiate, they give rise to common myeloid precursors (CMP) and 
common lymphoid precursors (CLP) 23. After that, CMP differentiate into erythrocytes and 
megakaryocytes, granulocytes, and macrophages. The CLP, give rise to all lymphocytes: B, 









































































































Figure 2.1 The process of hematopoiesis. (Adapted from Kaufman and Anderson 2003) 
Lineages: B/CFU = burst/colony forming unit, GEMM = granulocyte-erythrocyte 
macrophage and monocytes, Ba = basophil, Eo = eosinophil, Meg = megakaryocyte, E = 
erythrocyte, NK = natural killer cell. 
 
The fate of the progenitor cells once they have started differentiation was, until very 
recently, thought to be restricted and irreversible. Recent studies have reported that 
alternative lineage choices exist. Cumano, A. et al. described a bipotential B-cell/macrophage 
progenitor in adult bone marrow 24.  In in vitro culture it was demonstrated that some 
transcriptional combinations, such as CLP and CMP, are more probable to occur than others, 
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for instance the  B-cell/macrophage progenitor 25. Thus in hematopoiesis, lineage switching 
has been found to occur between cells whose genetic profile differs only in a few key genes. 
CLPs and CMPs represent the earliest point of differentiation between myeloid and lymphoid 
lineages 23. To differentiate them, CLPs and other downstream progenitors express the 
interleukin-7 receptor α-chain (IL-7Rα) 26, whereas CMPs represent the IL-7Rα- fraction of 
bone marrow. 
With regards to cell cycle behaviour, it has been found that a dramatic loss of 
repopulating activity in stem cells after the first cell division exists. In addition, sequential 
oscillations of repopulating activity have been observed associated to the cell cycle passage 
of a stem cells population. Proliferating HSCs have been found to decrease their ability to 
engraft in the S/G2/M phases of the cell cycle 27.  
HSC division is asymmetric because under homeostatic conditions the number of HSC 
remains relatively constant despite the fact that they proliferate. Hence, it is commonly 
assumed that individual stem cells can give rise to two non-identical daughter cells: one that 
can be a differentiated cell and the other maintaining stem-cell identity 28.  
 
2.1.1.2 Mobilisation and Apoptosis 
Since HSCs reside in the bone marrow, these cells have a notably motility, and, in response to 
specific signals, they can exit and re-enter the bone marrow HSC niches. These processes are 
known as mobilisation and homing, respectively 28. Several molecules are crucial for the homing 
process, including cell-surface adhesion integrins and selectins or homeostatic chemokines, such 
 33 
 
as CXCL12, which is involved in migration, adhesion and mobilisation and is expressed in 
stromal cells, including osteoblasts and vascular endothelial cells 29. The mechanism of stem cell 
mobilisation is still not clear; it seems to be a multistep process with a cross talk between 
cytokines and adhesion molecules. Clinical applications to support high-dose therapy have used 
cytokine-induced mobilisation in patients and healthy donors by employing the hematopoietic 
cytokine: G-CSF 30.  
 
2.1.2 Stem Cell Niche 
The maintenance and regulation of the HSC functionality is thought to be dependent on 
their specific microenvironment, termed the stem cell niche 28, they inhabit. Stem cell niches 
are part of the complex bone marrow architecture consisting of multiple cell types and the 
extracellular components produced by these cells, such as fibronectin, collagen, vitronectin 
and tenascin. They are located in the endosteum within the bone marrow cavity and they are 
composed by osteoblasts, osteoclasts and stromal fibroblasts 31. Stem cell niches can house 
stem cells indefinitely and control their properties. In particular, HCS self-renewal is 
regulated by the niches which prevent them from differentiating. HSCs remain in the niches 
in a quiescent state (G0 of the cell cycle) that can last for months; these are the ones that are 
efficiently engrafted following transplantation 32,33. Hence, these long-term quiescent HSCs 
do not contribute to the normal homeostasis of the hematopoietic system but form part of a 
reserve pool of HSCs that will be activated in the event of an injury or a disease. Therefore, 
they are located in a “storage niche”, which assists them in remaining undifferentiated in a 




Quiescent Niche Self-renewing Niche
MPP
termed the self renewing niche, has been stipulated, which ensures that one of the two 
daughter of a dividing stem cell maintains the parent stem cell properties while the other one 
becomes a differentiated progenitor. This type of niche is believed to be more complex than 
the quiescent niche, with quiescent stem cells anchored in the centre of the niche and the self-
renewing stem-cells located close to the niche border where the stimulus that induce 







Figure 2.2 Models of Bone Marrow Niches. The quiescent niche will maintain dormant 
HSCs long-term. The self-renewing niche produces multipotent progenitors but also retains 
the self renewal pool by asymmetric division. Adapted from Wilson, A. and Trumpp, A. 
Nature Reviews: Immunology. Vol.6. Pag. 93-106. 
 
Stem cell regulation is due to the presence and/or absence of specific positive or negative 
growth factors 36, which control the migration and homing of leukocytes to regions of injury 
or infections, as well as primitive hematopoietic cell proliferation. In addition, the ECM also 
contributes to the regulation of stem cell functions in the cell niche by presenting localised 
growth factors that are protected from proteolysis, and by expressing various different 
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adhesion molecules. For instance, the combinations of cytokines-fibronectin-HSC leads to a 
greater proliferation rate when compared with cytokines alone 37. 
Osteoblasts (OB) act as regulatory components of the HSC niche and produce 
hematopoietic growth factors. They are activated by parathyroid hormone (PTH) or the 
locally produced PTH-related protein (PTHrP), through the PTH/PTHrP receptor (PPR). 
Increasing the numbers of OBs causes an increase in the number of HSCs, mostly LT- 
repopulating HSCs, without an increase in any other type of cell. Use of the PTH/PTHrP 
receptors (PPRs) activates and increases the number of osteoblastic cells, producing a high 
level of the Notch ligand jagged 1 38. Hence, OBs regulate the stem cell niche in vivo and 
influence stem cell function through Notch activation. The receptor tyrosine kinase (Tie2) is 
expressed by HSCs and adheres to OB in the BM. The interaction of Tie2 with its ligand, 
Angiopoietin-1 (Ang-1), results in a pathway that is critical for mobilisation and recruitment 
of HSCs and has an important function in the physiology of postnatal angiogenesis and 
hematopoiesis 39. Tie2/Ang-1 also maintains long-term repopulating activity of HSCs, 
enhances the ability of HSCs to become quiescent, and induces adhesion to the bone, thus 
playing a critical role in the maintenance of HSCs in a quiescent state in the BM niche 40. 
 
2.1.3 Bone Marrow Vasculature 
The process of vasculature starts during embryogenesis forming the primitive vascular 
plexus 41 that is expanded during angiogenesis, which is strictly regulated and defined as the 






the maintenance of cellular homeostasis in the human body; all cells reside within 200 µm of 
a capillary 43. Folkman and colleagues demonstrated that angiogenesis played an important 
role in the tumor development, progression and metastasis 44 45.  
Blood flow has a major function in the physiology of hematopoiesis and bone 
remodelling. Blood supply in the bone marrow comes from six different groups of arteries 
named after their location. There are one or two nutrient arteries, which penetrate the cortex 
through the nutrient canal and then bifurcate into ascending and descending medullary 
arteries, called radial arteries, which containing branches that reach the inner face of the 
cortex; superior and inferior metaphyseal arteries, which anastomose with the nutrient artery 
system; superior and inferior epiphyseal arteries, which supply layers of physis by diffusion; 
and finally periosteal vessels connected by longitudinal anastomoses (see figure 2.3) 46. 
Arterial blood supply of the cortex is centrifugal and the venous flow is centripetal with 








Figure 2.3 Arteries involved in bone marrow blood supply. Adapted from Sambrook, P. Bone 





The marrow stroma is formed by a network of sinuses that enter the systemic venous 
circulation; hematopoietic cells are located in the intersinusoidal tissue spaces. These sinuses 
lead to a large central sinus from where the blood enters the systemic venous circulation 
through the emissary veins. In humans, there are three types of stromal cells: endosteal or 
bone-lining cells, adipocytes, and cells from the bone marrow vasculature, such as 
endothelial and abluminal cells, vascular smooth muscle cells from the media arterioles, 
pericapillary pericytes, and parasinusal myoid cells with cytoplasmic processes extended into 
the marrow cord 18. The sinus wall is composed of endothelial and an abluminal coat of 
adventitial reticular cells able of transforming into adipocytes; a thin membrane separates the 
two types of cells 47.  Myoid cells and pericapillary pericytes regulate stem cell behaviour by 
providing cytokinic mediators and anchorage sites. The cells from the bone marrow 
vasculature are critical for hematopoiesis. Endothelial cells regulate the efflux of mature 








Figure 2.4 Diagrammatic illustration of the basic structure of compact bone. The figure 
shows the different localisation of osteoblasts, osteoclasts and the bone marrow 






There is a close interaction between HSCs and endothelial cells; bone marrow endothelial 
cells differ from the rest of the vascular endothelial group in that they have the ability to 
maintain HSC in vitro 50. Specifically, they are functionally and phenotipically different from 
the other microvasculature endothelial cells, and are termed bone-marrow sinusoidal 
endothelial cells (BMECs) 51. These cells support myeloid and megakaryocyte progenitor 
expansion, whereas primary bone-marrow stromal cells release factors that inhibit 
megakaryocyte maturation 52. Consequently, megakaryocytes are produced in this type of 
secondary vascular niches and the rest of the cells are produced in the primary self-renewal 
and quiescent niches.  
 
2.1.4 Regulation of HSCs Processes 
Hematopoiesis is a complex process that is regulated by various types of molecules; such 
as cytokines. Cytokines are small secreted proteins which regulate immunity, inflammation, 
and hematopoiesis. They generally act over short distances and short time spans and very low 
concentrations. Stimulatory and inhibitory cytokines control hematopoiesis taking place in 
the intersinus spaces of the marrow. They are produced primarily from the endothelium and 
reticular cells located in the bone marrow stroma  9. The most studied cytokine receptors 
expressed on HSCs include tyrosine kinase receptors, the hematopoietic growth factor 
receptors, and the gp130 receptor family; some examples of tyrosine kinase receptors are Flk-
2/Flt3, the receptor for Flt3-ligand and c-kit. Both are expressed on very primitive HSCs and 
regulate the early stages of hematopoiesis 53.  Cytokines such as stem cell factor (SCF), 
granulocyte monocyte colony-forming unit (GM-CFU) and interleukin-3 (IL-3), activate the 
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adhesiveness of HSCs to the stroma through integrin activation. Granulocyte-monocyte 
colony stimulating factor (GM- CSF) and granulocyte-CSF (G-CSF) sustain proliferation of 
myeloid lineages; thrombopoietin enables the direct production of platelets and their 
precursor cells, megakaryocytes 13. Growth factors that are multipotent and have stimulatory 
activity on progenitor populations of different lineages include IL-3 and GM-CSF 54. Other 
GFs, such as IL-6, G-CSF, SCF and c-kit ligand synergise with the multipotent activities of 
GM-CSF and IL-3 55. Erythropoietin (EPO) and macrophage colony-stimulating factor (M-
CSF) work on the progenitor cell population of a single lineage 56. Some GFs are 
glycoprotein hormones that regulate proliferation and differentiation. They can act locally, 
where the cells are produced, or circulate in the blood. Each GF binds to target cells through 
specific receptors 57.  
Hematopoietic stem-progenitor cells attach to cellular and matrix components in the 
marrow through numerous adhesion receptors divided into six different groups 58 59: the 
integrins 60, immunoglobulins 61, lectins (selectins) 62, sialomucins 63, hyaladherin (CD44, H-
CAM) 64, and other receptors such as CD144, CD157 or CD38 9. Although the addition of 
exogenous cytokines to hematopoietic cell cultures may promote lineage-specific 
differentiation of CD34+ cells, they might also act in the opposite way and contribute to the 
loss of the ability to differentiate into specific lineages or to repopulate irradiated recipients. 
Specifically, addition of cytokines, such as IL-3, SCF and G-CSF, increases short-term 
expansion yet with a loss of immature CD34+ cells; thus limiting long-term engraftment and 
reconstruction 65. Recent studies, supported by the finding of loss of engraftment capacity of 
primitive hematopoietic progenitors that have undergone ex vivo expansion using exogenous 
cytokines, have indicated that the HSC properties of proliferation and maturation driven by 
 40 
 
cytokines are associated with the exit from Go quiescence and entrance into active cell 
cycling 66. 
Bone Morphogenetic Proteins (BMPs) are secreted polypeptide members of the 
transforming growth factor-β (TGF-β) superfamily. BMP-2, -4, and 6, which are the most 
common BMPs used in osteoblasts cultures, are 90% homologous in their amino acid 
sequence and, therefore, have similar activities.  BMPs play an important role in osteoblastic 
differentiation and function 67. Specifically, they are expressed in adult bone marrow and 
regulate the proliferation and differentiation of highly purified  primitive human 
hematopoietic cells from adult and neonatal sources 68. BMP signalling, through the BMP 
receptor type IA (BMPRIA), controls the number of HSCs by regulating the niche size. 
BMPRIA is found in bone marrow cells, including most of the hematopoietic lineages apart 
from the HSCs and most OBs 68. Even though BMPs are members of the TGF-β superfamily 
of polypeptides, their effects on osteoblastic cell differentiation and maturation vary. BMPs 
induce stromal cells to differentiate into the osteoblastic lineage, therefore increasing the 
number of insulin-like growth factor-I (IGF-I) target cells, namely, the mature osteoblasts 69. 
BMP-4 induced hematopoietic tissue in Xenopus and differentiated mouse embryonic stem 
cells into hematopoietic stem cells; it has also been reported to act as a survival factor 
protecting cellular function under conditions that normally lead to stem cell apoptosis.  
Research carried out by Bhatia et al underlines the role of BMP-4 in primitive hematopoietic 
stem tissue showing the function of BMPs as regulators of blood development well after 
tissue specification. Therefore, addition of factors, such as BMP-4, to the ex vivo cultures can 
result in an increase in the period in which repopulating cells can be maintained in culture 68.  
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2.1.5 HSCs Culture Systems 
 The ex vivo expansion of HSCs has been long-term goals of stem cell bioprocessing and 
tissue engineering. However, two main challenges remain, namely, the inability to attain the 
self-renewal capacity of HSCs and the inability to accomplish the appropriate differentiation 
towards the desired lineage. Tissue Engineering has been defined as the science of design and 
manufacture of new tissues for the functional restoration of the impaired organs/tissue due to 
disease, trauma, and tumours. It relies on the disciplines of developmental biology, 
biomaterials, biomechanics, and bioprocess engineering 70. In order to investigate and 
achieve the expansion of HSCs, several parameters need to be taken into account. 
2.1.5.1 Parameters that influence HSC cultures 
Choosing the optimal culture parameters for ex vivo expansion is a major challenge. 
Hematopoietic cell cultures have traditionally been classified as stroma-free or stroma-
dependent 71. Even though stroma-free are easier to maintain and standardise, stroma-
dependent cultures possess certain advantages. Specifically, they support a higher expansion 
of CD34+ cells and colony formation (CFU-Cs) as they provide a better microenvironment 
for HSCs proliferation. In HSCs cultures, autologous stromal cells is the source normally 
preferred, although different sources of stromal cells used to mimic the microenvironment 
have been found to induce different hematopoietic pathways 72. The use of acellular stromal 
components, such as fibronectin, has also been considered; nevertheless, the use of 
fibronectin alone is not enough to replace the factors present in the in vivo microenvironment 
required to sustain primitive HPC and HSCs in vitro 65. 
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In recent developments, the serum-free expansion of HSCs has been demonstrated as 
long as an appropriate mixture of cytokines is provided 53. Additionally, it has been suggested 
that direct contact of primitive hematopoietic stem cells with stromal cells may decrease the 
proliferative activity of the primitive hematopoietic stem cells 73. Although the addition of 
large amounts of cytokines to HSCs cultures enables their expansion, it is very expensive and 
distorts the in vivo humoral microenvironment 19. SCF, TPO, FL, interleukins (IL)-1, -11 and 
-6 are some of the cytokines that can be used for HSCs expansion. In addition, other variables 
that affect the total outcome, such as serum replacement, purity of CD34+ cells, initial cell 
concentration, and the duration of the culture, need to be considered 74. In particular, the use 
of human serum albumin as a serum replacement in clinical applications has been 
demonstrated 75. Serum is a source of essential nutrients for cells but it also introduces 
complications, such as a lot of variability, renders the medium undefined, and contains 
inhibitory factors, such as transforming growth factor (TGF)-β which inhibits proliferation of 
erythroid precursors and induces the differentiation of bust-forming units (BFU-E) into more 
mature erythroid cells 13. Although serum contains growth-required compounds including 
hormones, growth factors, and binding proteins, it is a potential source of bacterial, 
mycoplasmal, and viral and foreign contamination 76. In addition, cell proliferation capacity 
is higher when using CD34+ cells as the starting population; the use of more mature cells for 
HSCs expansion have been proven to have suppressive effects on progenitor expansion, 
especially in static cultures where all cellular by-products remain in the culture. The effect of 
the initial cell concentration also influences the number of cells generated in static cultures 77. 
HSC culture have been investigated using 2-D and 3-D systems, below is a description of the 
techniques used so far for their expansion.  
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2.1.5.2 Static cultures 
HSCs expansion using static cultures includes the use of well-plates, T-flasks and 
unmixed gas-permeable blood bags. The first static culture system established was the 
murine long-term bone marrow culture (LT-BMC) developed in the mid-1970s using the 
Dexter culture medium. It appeared to support hematopoiesis ex vivo for several months. 
However, human LT-BMCs, first developed in the early 1980s, exhibited exponentially 
decreasing numbers of total and progenitor cells with time; even though the rate of decline 
was slowed by the addition of GFs, stem and progenitor cell expansion was not obtained 
because static cultures could not support high cell densities 78. Consequently, for all their 
usefulness, static cultures have certain limitations, such as cell expansion capacity, their non- 
homogeneous concentration gradients (pH, dissolved oxygen, metabolites, etc.), limited 
surface area growth potential and scale-up challenges 72.  
 
2.1.5.3 Stirred vessels 
Stirred vessels have advantages over most static in terms of  sampling, data collection, 
and control of medium conditions 61. BM monuclear cells (MNCs) have been effectively 
expanded in stirred vessels serum-containing conditions, whereas PB and CB MNCs as well 
as CD34+ cells have been expanded in both, serum-containing and serum-free media 79. The 
culture volume required is reduced and the cell density achieved is higher than in static 
systems. In stirred vessels, proliferation is dependant on agitator design (shear stress 
becoming a strong limitation) and the inoculum density 72. 
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2.1.5.4 Perfusion Systems 
In order to overcome these limitations, bioreactors have gained increasing importance in 
tissue-engineering to provide the conditions necessary for the cells to regenerate functional 
tissue. Perfusion bioreactors maintain a constant supply of GFs and nutrients by continually 
replacing culture medium and analyse its consumption and production. These studies 
suggested that changes in the perfusion schedule of the culture considerably influenced the 
secretion of GFs by stromal cells 80.  There are three types of perfusion bioreactors which are 
normally used for the expansion of long-term initiating cells (LTC-IC) and colony forming 
cells (CFCs): flat-bed perfusion systems, grooved-bed perfusion systems, and the hollow-
fibre system. 
 Flat-bed perfusion bioreactors continually replace culture medium, maintain 
moderately the culture conditions and support stroma formation; however, they are not 
suitable for large scale production and do not completely eliminate gradients in culture 
conditions 72. They contain inclined culture chambers with low laminar flow for the removal 
of non-adherent cells during perfusion. This system has been tested for the expansion of all 
types of hematopoietic progenitor cells from all the HSC sources and when supplemented 
with the correct cytokines and under optimal conditions, flat-bed perfusion systems support 
expansion of LTC-ICs and CFU-GM 81. Grooved-bed perfusion system contains 
perpendicular to the flow chambers with multiple microgrooves and thus can provide a 
higher perfusion rate. However, this system presents disadvantages in monitoring and 
controlling the culture due to the inhomogeneities in the concentration of soluble factors 
caused by the isolation of cells from the main convective flow of the medium. This system 
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supports the expansion of CFU-GM and maintains LTC-IC 82. Hollow-fibre system present 
some disadvantages from the design such as scale-up difficulties that arise because of the 
spaces between the fibre modules are not kept constant therefore resulting in fluctuations in 
oxygen transfer and complications when trying to monitor culture parameters 83. 
2.1.5.5 3-D Culture Systems 
In order to mimic the in vivo bone marrow architecture and enhance the cell-cell and cell-
matrix interactions, the design of 3-D culture system has been investigated based on the 
selection of an appropriate porous carrier that permits stromal cell adhesion and nutrient 
diffusion. Many different 3-D culture systems for the expansion of HSCs have been studied; 
one of them is the 3-D tantalum-coated porous biomaterial (TCPB), which has an open 
porosity of 85%, and has an open pore lattice-like structure in which all the surfaces are 
coated with tantalum, a biocompatible metal 84. TCPB supports HPC viability, multipotency, 
LTC-IC survival and retroviral transduction in vitro in the absence of exogenous cytokines. 
When compared with conventional culture systems, TCPB cultures yielded greater 
percentages of CD34+ and CD34+/38- cells and better transduction efficiencies in both short 
and long term cells 65. Packed-bed bioreactors have also been investigated for human bone 
marrow cell attachment and growth; by examining thin-sections of the paraffin-embedded 
microspheres it became apparent that a 3-D LT-BMC growth configuration was established 
with success, resulting in a 3-D culture system that resembled the bone marrow tissue 
structure in vivo 55. Other 3-D systems developed with some success have used collagen 
spheres or CellFoam™ 85; however these systems produced very few progenitors, or 
supported only multilineage differentiation. Li et al studied the use of a non woven 
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polyethylene telephthallate (PET) matrix and human cord blood to stimulate the marrow 
microenvironment86. Other alternatives use Cellfoam ™, a porous biomatrix that mimics the 
in vivo spatial arrangements of cytokine and ECM distribution 66. It was demonstrated that 
such system, combined with supplementation with low-dose cytokines, could expand both 
mature as well as immature HPCs. Low concentrations of cytokines were selected to mimic 
the steady state in vivo hematopoiesis. The cytokines used were SCF and Flk-2/Flt-3 ligand 
and achieved high yields enriched for multipotent hematopoietic progenitors, maintained for 
extended periods of time. 
 
2.2 ACUTE MYELOID LEUKEMIA (AML) 
AML is a form of leukemia, a rapidly progressing cancer of the blood, affecting 
immature cells of the bone marrow. It differs from other cancers in that hematopoietic and 
lymphoid stem cells do not stay in one location, but circulate in the blood stream and migrate 
into the various tissues. Depending on the cell type, it can be divided into two groups: 
myeloid or lymphoid leukemias. The necessity of identifying the pathways and stimuli 
involved in the self-renewal processes of both, normal and leukemic stem cells, is obvious in 
order to understand the events that lead to the development of cancer. Currently, it is 
unknown which are the abnormalities required to instigate leukemic transformation. 
Leukemic stem cells can be defined as cancer cells that have the capability of self-renewal, 
and, therefore, produce more cancer stem cells as well as more differentiated non-
tumorigenic cancer cells. Although, it has to be noted that in leukemia, only a minority of 
stem cells have the ability to proliferate and form new tumours 87. The origin of the cancer 
 47 
 
stem cells is still unclear; however, as multiple mutations are needed for a cell to become 
cancerous, it is improbable that all the mutations occur in the short-lived progenitors cells. As 
a result, it is likely that cancer stem cells are derived either from normal self-renewal stem 
cells or from progenitor cells that have undergone oncogenic mutations 88.  
Table 2.1 Comparison between Normal and Leukemic Stem Cells. The main characteristics 
of HSCs are compared with those of LSCs and the differences can be appreciated. 
 
 Stem Cells Leukemic Stem Cells 
Self-Renewal Yes Unlimited 
Feedback removing mechanism Yes No 




No GM / Accumulation 
of errors 
 
Leukemic cells, similar to normal hematopoietic cells, are subjected to the influence of 
the hematopoietic microenvironment. In contrast, they may receive additional protection 
from endogenous apoptotic mechanisms. The interaction of the leukemic cells with stromal 
layers inhibits their apoptosis, thus causing the enhanced growth of leukemic cells. In 
addition, their interaction with cytokines has also a growth promoting effect 88.  
 
2.2.1 Origin of Leukemic Stem Cells 
Leukemias arise from the clonal expansion of a single cell and then are sustained by 
leukemic stem cells (LSCs). Heterogeneity in LSC self-renewal potential supports the 
hypothesis that they are derived from normal HSCs. 
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distinct LSCs that are hierarchically organised 89. Thus, we can differentiate between short-
term, long-term and quiescent long-term LSCs. They retain many characteristics of normal 
HSCs and can arise in two different ways. One possibility is that mutations occur by directly 
targeting HSCs; the other possibility could be that more differentiated cells, that do not 
display stem cell characteristics, mutate into cells with stem-like properties 90. Therefore, 
leukemia may represent erroneous normal hematopoietic development, where the leukemic 
cells retain aspects of normal developmental programs 89. Research studies carried out by 
Dick et al 91, identified leukemia-initiating cells (LICs), which have a very similar phenotype 




Figure 2.5 Origin of Leukemic Stem Cells and different subtypes of AML. A normal HSC 
can give rise to two different stem cells depending on the development or not of a 
leukemogenic event. Adapted from: Uy G. Leukemic stem cells in AML. Washington 





Conventionally, AML is classified into 8 subtypes following the French-American-
British (FAB) standards, which differentiate depending on morphology, degree of cell 
maturation, and expression of lineage differentiation markers 92.  
Table 2.2 French-American-British (FAB) Classification of AML. The classification 
distinguishes the different types of AML depending on the degree of maturation of the cells 
affected. 
FAB Subtype Name Approximate % of adult 
AML patients 
M0 Undifferentiated acute 
myeloblastic leukemia 
5% 
M1 Acute myeloblastic leukemia 
with minimal maturation 
15% 
M2 Acute myeloblastic leukemia 
with maturation 
25% 
M3 Acute promyelocytic 
leukemia 
10% 
M4 Acute myelomonocytic 
leukemia 
25% 
M5 Monocytic leukemia 10% 
M6 Acute erythroid leukemia 5% 




Leukemias do not arise by a simple mutation. They require the cooperation between two 
classes of mutations: a) mutations in RAS, Flt-3, or KIT, which confer a proliferative and/or 
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survival benefit to hematopoietic progenitors but does not affect differentiation; b) mutations 
that affect the PML/RARa, AML1/ETO, HOX gene fusions, or MLL gene rearrangements, 
which influence hematopoietic differentiation and may contribute to the expansion of 
hematopoietic progenitors. This explains why leukemia cells are characterised by enhanced 
proliferation and survival of cells and impaired differentiation 93. MLL fusion genes are part 
of the cause of leukemia through dysregulation the expression of the HOX gene 94.  
AML is a heterogeneous disease which has been proven to evolve from leukemic 
transformations occurring at the level of immature multipotent CD34+CD38- cells. It is 
induced by leukemia-associated fusion proteins that normally work as activation signs or as 
transcriptional regulators; thus directly interfering with the hematopoietic differentiation 
program. There are at least four fusion proteins involved in AML including: MLL/CBP, 
MLL/p300, MOZ/CBP and MOZ/TIF2. These fusion proteins are recruited by transcriptional 
factors who bind to cognate DNA sequences in the promoter of target genes 95. The MOZ-
TIF2 protein is believed to act in the regulation of target genes through aberrant histone 
acetylation 96. The results presented by Jamieson et al (2004) showed that the MOZ-TIF2 
protein provides myeloid progenitors with self-renewal capacity leading to their 
immortalization in vitro and to their ability to produce AML following transplantation in 
vivo. Another AML-associated fusion protein, MLL-ENL, transforms committed progenitor 
cells with no-self-renewal capacity, into cells that have it. This highlights the importance of 
the self-renewal capacity as a critical leukemogenic event that should be considered together 
with the level of commitment of the targeted cells in AML. AML cells reside in a quiescent 

















being carried out at the moment against leukemias are targeting active cell populations and, 
thus, the current treatments are not being effective against AML stem cells 90. 
In acute leukemia it is common the fusion of transcription factors such as: core binding 
factor (CBF), retinoic acid receptor alpha (RARα), HOX and ETS family members. CBF, 
also known as AML1, regulates the expression of genes that are important in normal 
hematopoietic differentiation. Interference in the function of CBF through chromosomal 
translocation produces a disruption of HSC differentiation 95. When transcriptional factors 
fuse, there is always a chimeric protein that is a dominant negative inhibitor of the wild-type 
protein, as in the case of AML1/ETO, where also the normal AML1 protein is expressed. 
HOX family members as well as proteins that are upstream regulators of HOX gene 








Figure 2.6 CBF transcriptional complex aberrations in leukemia. This figure shows the 
Core Binding Factor and the different chromosomal translocations and how that affects 




AML often develops after a gene rearrangement which leads to the activation of the IL-3 
receptor perturbing the signal transduction pathway involving the receptor tyrosine kinase 
(RTK) which stimulates cell proliferation and inhibits apoptosis 21. These ligand binding 
receptors (RTK) include PDGF, Fms, c-kit, and FLT3 5. Mutations in these receptors have 
been described frequently in AML. Mutations in the kinase domains of Fms have been 
described in 5-10% of selected AML cases; however mutations in the FLT3 RTK are the 
most common. The FLT3 receptor gene is mutated approximately in one third of patients 
with AML and enhances proliferation and viability through constitutive activation of the 
tyrosine kinase. PKC412 (N-benzoyl staurosporine) is a highly active inhibitor of both 
mutant and wild-type FLT3 tyrosine kinases and selectively induces G1 arrest and apoptosis 
of Ba/F3 cell lines expressing mutant FLT3 95. Hence, PKC412 is a future candidate to be 
tested as an anti leukemia agent in AML patients with FLT3 receptors. Whether mutant or 
not, FLT3 is frequently over expressed in AML, playing an important role in proliferation of 
leukemia blasts 94. A different mutation that causes abnormal signal transduction is the ras 
mutation; that is a mutation in N-, k-, or H- ras and occurs in approximately 10-30% of AML 
cases. These point mutations develop in codons 12, 13, and 61 and prevent the hydrolysis of 
ras-GTP causing the activated ras to be constitutively “stuck” in the on position 5. 
Translocations causing the activation of the ras pathway have also been identified. 
2.2.2 Comparison between Normal and Leukemic Stem Cells 
Leukemic stem cells obtain the ability of self-renewal from normal stem cells and use this 
machinery for their own expansion; they also share many pathways associated to normal 
stem cells, such as apoptosis. Should the concept of leukemic stem cells hold, then there are 
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other concepts of tissue organisation that may also be true, such as the dependency of the 
leukemic stem pool of a specialised niche. It has been shown that there is a different 
sensitivity between normal and leukemic cells to the signals derived from the niche. This is 
still under investigation but it has been shown that there are inhibitory signals towards the 
malignant cells or stimulatory signals towards the normal cells that shift this relative balance 
98. The leukemic cells escape the growth-inhibitory signals provided from the self-renewal 
niche that maintains the normal HSCs in quiescent state and prevents their unlimited 
differentiation. Therefore, it has been suggested, but not yet proven, that the LSCs might 
reside in the other type of niches, the vascular niches, where they transferred 31. Stem cells 
prevent apoptosis by expression of the oncogene bcl-2; therefore if sustained expression of 
this oncogene occurs, there will be an increase in the number of HSCs in vivo, suggesting that 
cell death has a role in regulating homeostasis. Notch activation promotes HSCs self-renewal, 
or at least the maintenance of multipotentiality 87.   
Another protein that plays a very important role is the Wnt signalling pathway. Wnt are 
proteins that signal intracellularly and, when deregulated, could lead to the development of 
cancer. Wnt is highly expressed in normal bone marrow HSCs and, when the expression of 
Wnt is inhibited, HSCs will not proliferate, the death rate of HSCs in vitro is increased, and 
the reconstitution in vivo is reduced. It can induce cell differentiation by preventing β-catenin 
degradation 67. The Hedgehog Hh and Wnt signalling pathways are known to direct growth 
and patterning during embryonic development. These pathways, contribute to the signals 
defining the adult stem-cell niche. Therefore, even transient inhibition of these pathways will 
result in severe toxicity producing extreme malformations in embryos and the improper 
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regulation of multiple growth functions is related to the high frequency of mutations in the 
Hh and Wnt pathways in specific tumor types.  
As mentioned previously, angiogenesis has a very important function in tumor 
development, progression and metastasis 42, therefore contributes to hematological 
malignancies. Endothelial growth factors VEGF and basic fibroblast growth factor (bFGF) 
are expressed by AML cells and may play a role as paracrine growth factors in the 
development of AML. Samples of bone marrow taken from an untreated patient with AML 
showed an increased microvessel density (MVD) compared with samples from control 
patients 99. 
The above processes are possible by the mediation of different molecules; myeloma cells 
adhere to the BM by several types of plasma membrane receptors, for instance β1 integrins. 
These cellular binding events stimulate the secretion of the cytokines IL-6 and TGF-β from 
the BM stromal cells, and IL-1β, TNF-β, IL-6, and VEGF from myeloma cells 100. The 
production of IL-6 is of special importance as it ignores the apoptotic signals mediated by the 
Fas antigen stimulation (CD95) and chemotherapeutic drugs, becoming one of the main 
survival and growth factors for myeloma present in the marrow.  Other growth factors 
include G-CSF, GM-CSF, SCF, HGF, etc.... IGF-1 has a important function; it is an 
endocrine factor involved in the metabolic control and anti-apoptic functions in the BM 101. 
The non-collagen proteins of the bone, as well as osteoclasts and osteoblasts, also play a role 
in the development of leukemia. The osteoclasts clear out the fatigued bone and the 
osteoblasts rebuild the new bone. A well established balance is found in normal 
hematopoiesis but in patients with multiple myeloma, bone resorption by osteoclasts is 
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increased and is higher than bone formation. The rise in osteoclast activity is caused by 
osteoclastic activating factors (OAFs) known to be released by tumor cells. OAFs produce 
another growth factor called RANKL. TNF increases the expansion and growth of osteoclasts 
cells and their activity resulting in the development of myeloma. The increase of the 
osteoclast activity also produces the release of IL-6, which, as already discussed, contributes 
to tumor cell growth and survival. 
The ECM and its enzymes, such as matrix metalloproteinases (MMP) also contribute to 
regulate cell behaviour during angiogenesis by releasing factors that bind to the ECM. 
Furthermore, MMPs during cancer progression, degrade the cancer cells’ most important 
physical barriers, which are components of the ECM 102, contributing to cancer progression42. 
Self-renewal, proliferation and commitment in normal and leukemic hematopoiesis are 
also regulated by the Polycomb group genes. They regulate cell fate in several other tissues 
through diverse mechanisms. It is therefore not surprising that PcG genes lead to pleiotropic 
phenotypes when mutated and have been associated with malignancies in several systems in 
both mice and humans 103. There are around 40 different types of Polycomb genes and their 
function seems to have been conserved throughout evolution. Some of the new insights into a 
role for the PcG cellular memory system in regulating normal and leukemic hematopoiesis 
have been investigated. As an example, the expression of the Bm1-1 gene, expressed in 
primitive human and mouse bone marrow cells, showed to be mandatory for the correct 




2.2.3 Culture of Leukemic Cells 
The culture of leukemic cells in vitro is extremely difficult and most attempts have failed. 
Human leukemic cell culture were first studied by several groups in the late 1960’s 105-107, 
which used methylcellulose clonogenic assays previously developed to for murine 
hematopoietic progenitors and modified to be used with human cells. In 1969, Metcalf and 
colleagues grew myelomonocytic leukemia cells in vitro using a technique that relied on the 
immobilisation of single cells in a semisolid medium; by doing that, the movement of the 
cells was restricted and it was possible to evaluate the number of progeny derived from the 
parent cell after short term culture. The cells produced were called AML colony forming 
units (AML-CFU) but lacked self-renewal capacity 108,109. Later studies were carried out on 
the self renewal capacity of AML cells in vitro but the clonogenic assays showed no 
detectable self-renewal capacity and growth could only be carried out for short periods of 
time 109. To overcome these problems, AML cells were cultured in suspension which 
permitted proliferation up to 70 days when the culture was maintained at very high cell 
densities and with the addition of high concentrations of exogenous growth factors 110. In 
1996 Sutherland et al. developed an optimised cocktail of growth factors that maintained the 
culture for longer, independent of cell concentration 111. Still the drawback of the clonogenic 
assays was that they could not maintain true LSC expansion; the problem still remains 
unsolved. 
Nowadays researchers use cell lines to investigate AML and use the direct seeding of the 
cells directly into suspension, although the continuity of the cell line is not guaranteed and 
varies between different reports. Even though the reasons for this failure remain unknown, 
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the culture deterioration causes the cessation of multiplication of the leukemic cells and 
overgrowth by normal fibroblasts, macrophages, or lymphoblastoid cells. The addition of 
regulatory proteins, such as EPO, IL-2, IL-3, IL-6, SCF, etc, to the leukemic cell lines, 
increases the chances of success by overcoming the period where the leukemic cells stop 
proliferating. However, an incorrect selection of nutrients and growth factors for these cells 
















Goals and Objectives 
 
 
The ex vivo cultivation of leukemic cells in two dimensions is extremely difficult 
without the addition of exogenous cytokines to the culture 113. Survival of AML blasts is 
enhanced if they are co-cultured with stroma or fibroblasts, suggesting that they are 
dependent on the structure, adhesion proteins and cytokine expression of their bone marrow 
microenvironment for survival114,115. The study of the impact of these physical-chemical 
influences on normal and leukemic bone marrow, and the process of leukemogenesis is not 
only limited by the requirement of exogenous cytokines for the maintenance of such cells in 
culture, but also by the lack of a three dimensional growth environment, which is not 
supported by 2-D cultures.  
The proposed thesis focuses on the development and optimisation of a 3-D culture 
system for the culture of leukemic cells in the absence of exogenous cytokines. Since the 
nature of the scaffold affects cell attachment, adhesion, growth and differentiation, initial 
studies on scaffold selection, fabrication, and surface modification was conducted using 
AML cell lines to ensure that primary AML cells were not wasted. Although AML cell lines 
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are already cytokine-independent in 2-D static cultures, this primary study of cell lines in 3-D 
focusing on the material and physical culture requirements required by AML cells should 
clarify the environmental needs of primary cells as well. Since primary AML is a 
heterogeneous disease, the system was optimised for the culture of different AML cell lines 
prior to the evaluation of primary AML cells.  
The possibility of mimicking the bone marrow structure seemed as a solution to 
overcome the problem of culturing AML cells ex vivo. By recreating the same environment it 
was hypothised that cells would survive for long periods of time and they could be 
investigated in their natural environment and without the addition of external growth factors, 
therefore maintaining the self-renewal potential.  
The properties that the ideal scaffold supporting an ex vivo HM can be defined as 
follows: 
 Highly porous. The scaffold should have a porosity of 80-95% and good pore 
interconnectivity to provide space for cell adhesion, migration, proliferation, ECM 
production and nutrient diffusion. 
 FDA approved to be used in tissue engineering applications. If the scaffold is 
biodegradable its by-products should not induce toxicity to the cells. 
 Pore size of <100µm in order for the seeded cells to penetrate throughout the 
scaffold. 




The specific objectives of this thesis are outlined as follows: 
 Fabrication and characterisation of 3-D scaffolds.  
 Establishment and characterisation of 3-D culture system using AML cell lines. 
 Optimisation and surface modification of scaffolds for AML cell culture.  





















Materials and Methods 
 
      
 
4.1 MATERIALS 
4.1.1 Cell lines 
Three well-characterised human leukemic cell lines were studied: K-562 (Human 
erythromyeloblastoid leukemia cell line ATCC®, UK; CCL-243), originally derived from a 
patient with blast crisis of chronic myeloid leukemia; HL-60 (ATCC®, UKCCL-240, from a 
patient with acute promyelocytic leukemia); and Kasumi-6 (ATCC®, UK; CRL-2775; acute 
myeloid leukemia with differentiation). These particular cell lines are often used for the study 
of leukemia in 2-D cultures and were chosen because of the different properties and stages of 
leukemic differentiation inherent in each; which would enable the optimisation of scaffolds 
for future use with most if not all subtypes of leukemic cells. The K-562 and HL-60 cells 
were cultivated in Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen Ltd, UK) 
supplemented with 10% and 20% v/v, respectively, of Fetal Bovine Serum (FBS heat 
inactivated, Invitrogen Ltd, UK). Kasumi-6 cells were grown in Roswell Park Memorial 
Institute-1640 (RPMI-1640) (ATCC®; 30-2001) supplemented with 20% v/v FBS and 
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Granulocyte Monocyte Colony-Stimulating Factor  (GM-CSF) 2ng/ml (R&D Systems 
Europe Ltd). A more detailed description of the property and development of the cell lines 
can be found in Chapter 6. 
4.1.2 Polymers 
Polymers under study were: Purasorb® Poly(D, L-lactide acid) (PDLLA; Mw: 250,000 
Da) and Poly(lactide-co-glycolic acid) (PLGA; Mw: 250,000 Da) purchased from PURAC 
Biochem (Gorinchem, The Netherlands); Polyurethane (PU; Mw: 125,000 Da) was supplied 
by Noveon (Belgium) and Poly(methyl methacrylate) (PMMA; Mw: 77,000 Da) was 
purchased from Röhm GmbH & Co (Germany); Polystyrene (PS; Mw: 250,000 Da) was 
obtained from Acros Organics (New Jersey, USA) and Polycaprolactone (PCL; Mw: 66,000 
Da) from Fluka (UK). A more detailed description of the scaffolds and individual property’s 
can be found in Chapter 5. Organic solvents used for the fabrication of the polymer 
constructs were: Dimethylcarbonate (DMC, 99% in purity), Dioxane (99% purity) purchased 
from Sigma-Aldrich (Dorset, UK) and Benzene (AnalaR®) from VWR International 
(Leicestershire, UK). Deionised water from NANOpure system (Barnstead, Dubuque, IA, 
conductivity 1.8 MΩ/cm) was used. The proteins used were: bovine plasma fibronectin and 
collagen type I (acid soluble from calf skin) purchased from Sigma –Aldrich (Dorset, UK). 
MTS-based CellTilter 96® AQueous Assay was from Promega (Madison, USA). T-flasks and 





4.2 SCAFFOLD FABRICATION 
 Highly porous foams (pore size 100-250 µm, porosity 65-95%) were fabricated by 
thermally induced phase separation (TIPS) of polymer solutions (5 wt% in the solvent) and 
subsequent solvent sublimation via freeze drying. TIPS process is a very versatile method 
which has many parameters involved, such as the type of polymer, polymer concentration, 
solvent/non-solvent ratio, and quenching temperature; by varying one of these parameters a 
wide range of polymeric structures can be produced. This technique is based on the 
thermodynamic mixing of a homogeneous polymer-solvent solution into a polymer-rich 
phase and a polymer-poor phase. It uses thermal energy as a latent solvent to induce phase 
separation. The polymer solution is quenched below the solvent freezing point and then is 
freeze-dried to produce the pores in the structure 116. Table 4.1 shows the appropriate solvents 
used for each polymer.  














The polymer solutions were transferred to a lyophilisation flask (Figure 4.1), which was 
immersed in liquid nitrogen for PLGA, PDLLA, PMMA, PCL and PS or kept at -86oC for 
PU and maintained at that temperature for 2 h. The frozen mixture was then transferred into a 
cryostat bath (Figure 4.2) maintained at a constant temperature of -15oC and the solvent was 
vacuumed to 10-2 mbar for 48 h. Prior to cell seeding, the scaffolds were cut into cubes of 







Figure 4.1 Lyophilisation flask used to prepare the scaffolds. The flask was 18 cm in 
diameter and 7 cm height and the petri dish containing the dissolved polymer was placed 
inside and then sealed with the flask lid.  The equipment was then moved to the ethylene 







Figure 4.2 Cryostat bath where the scaffolds were kept at -10oC while being vacuumed to 10-
2mbar.  The flask was placed inside the cryostat bath and connected to the extraction pump 
and to the cooling trap where the solvent was collected. 
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 Sterilisation was done using a combination of 8 min under UV light (230v, 50Hz, 0.14A, 
Kendro Laboratory Products UK) and immersion for 2 h in Ethanol (70%); the scaffolds were 
then washed twice for 5 min in PBS before adding the media and placing in a humidified 








Figure 4.3 Synthetic polymer scaffold preparation diagram. The figure shows the different 
steps involved in polymeric scaffold preparation, creation and later cell seeding and culture. 
 
4.2.1 Protein Coating 
Scaffolds were coated with collagen type I from calf skin and/or fibronectin from bovine 
plasma. The foams were cut and pre-wetted by immersion in ethanol (70%) for 1 min and 
then transferred into phosphate buffered saline (PBS; Gibco, UK) for 20 min. The scaffolds 
were then placed individually into eppendorf tubes containing PBS and then centrifuged for 
10 min at 3,630 g; once the cycle was finished, the scaffolds were transferred into new 
eppendorf tubes containing different protein concentrations: 125 µg/ml and 62.5 µg/ml of 
collagen type I soluble in 0.1M of acetic acid (Fisher Scientific, UK) and dissolved in 
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deionised water from a NANOpure (Barnstead, Duque, IA, conductivity 1.8 MΩ/cm), and 25 
µg/ml and 50 µg/ml of fibronectin diluted  in deionised water. A combination of collagen and 
fibronectin using the low concentration (62.5 µg/ml of collagen type I + 25 µg/ml of 
fibronectin) was also used by mixing the two proteins together. The foams were centrifuged 
at 1420 g for 20 min. In order to unblock the surface pores, and allow the cells seeded to 
penetrate deeper into the scaffold, the scaffolds were centrifuged one more time into new 
eppendorf tubes at 910 g for 10 min in PBS. The protein coated scaffolds were placed in 
single eppendorf tubes in the orbital incubator at 3 g (Stuart Scientific UK, SI 50) for 1 d at 
ambient temperature.  
4.3 CELL CULTURE 
4.3.1 Leukemic Cell Lines Seeding and Culture 
Three human leukaemic cell lines were studied: K-562, HL-60 and Kasumi-6. The cells 
were cultivated in standard polystyrene non-pyrogenic tissue culture flasks and in a 
humidified incubator at 37oC, 5% CO2 using the protocol recommended by the cell line 
provider, at a seeding density of 3.5x104 cells/cm3. For scaffold cultures, 100µl of cell 
suspension (5x105 cells/scaffold) were seeded onto the sterile scaffolds (both protein- and 
non-protein-coated), placed in 24 tissue culture plates and incubated for 15 min at 37oC and 
5% CO2
 before adding 1.5 ml of culture medium in order not to wash the cells out and allow 
time for settling down. Scaffold cultures seeded with cells underwent a half-medium 
exchange every other day and were otherwise treated in the same way as cell cultures done in 




4.3.2 MNC Separation and Cord Handling 
Cryopreserved human umbilical cord blood was obtained from the London Cord Blood Bank 
(London, UK), in accordance with regulatory and ethical policies (Harrow Research Ethics 
Committee No. 05/Q0405/20). Cryopreserved human cord blood cells were thawed in a 37oC 
water bath and gently aspirated from the blood bag using a 10 ml syringe and 18G needle. 
The aspirated cord blood was placed drop-wise into two 50 ml centrifuge tubes, each 
containing 30% (v/v) fetal bovine serum (FBS; GIBCO Invitrogen) and Iscove’s Modified 
Dulbecco’s Medium (IMDM; GIBCO Invitrogen) and centrifuged at 180 g for 10 min. 
Supernatant was gently aspirated using a sterile Pasteur pipette and the remaining cells were 
re-suspended in 30% (v/v) FBS and IMDM solution. This wash procedure was repeated twice 
and cells were collected into a single 50 ml centrifuge tube. MNCs were isolated from whole 
cord blood cells using Ficoll-Paque PLUS (Amersham BioSciences) via density-gradient 
centrifugation. Cord blood cells were suspended in 2% (v/v) FBS and IMDM, and the Ficoll-
Paque PLUS solution was gently layered under the cell suspension before being centrifuged 
at 400 g for 35 min. The middle buffy coat layer which contains the mononuclear fraction 
was gently removed using a sterile Pasteur pipette. 
4.3.3 Cord Blood Seeding and Culture 
CB MNCs were cultivated on scaffolds as follows: 100 µl of cell suspension (seeding 
density varied from 2.5 x 106  to 6 x 106 cells/scaffold) were seeded onto the sterile scaffolds 
(both protein and non-protein-coated), placed in 24 tissue culture plates and incubated for 15 
min at 37oC and 5 % CO2 before adding 1.5 ml of culture medium. Scaffold cultures seeded 
with cells underwent a half-medium exchange every other day and were otherwise treated in 
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the same way as cell cultures done in flasks. Long-term culture (LTC) medium was prepared 
by supplementing Iscove’s modified Dulbecco’s medium (IMDM) (Invitrogen Ltd, UK) with 
30% (v/v) of Fetal Bovine Serum (FBS heat inactivated, Invitrogen Ltd, UK) and 1% (v/v) 
Penicillin/ Streptomycin (Gibco, UK). 
4.4 ANALYSIS 
4.4.1 Scaffold Seeding Efficiency 
 After 24 h in culture, the seeded scaffolds were transferred to a new well plate and the 
number of cells remaining in the old medium was counted using the hemocytometer. To 
perform the cell count, 20 µl of the cell suspension was added to 20 µl of Erythrosin B 
(ATCC®, Manassas, VA). 10 µl of the solution was used to fill both chambers of the 
haemocytometer, making sure there were no air bubbles. Under light microscope (Leica DM 
microscope, Milton Keynes, UK) the number of viable (unstained) and non-viable (stained 
red) cells was counted in five 4x4 squares (or 0.1 cm2 area). Eq. 1 was used to determine the 
cell seeding efficiency. 
No. of viable cells/ml = Average No. of cells per 0.1 cm2 area x 104 (correction factor for 
volume of area indicated by brace) x 2 (dilution factor)             Equation: 1 
4.4.2 Cell Proliferation 
Changes in the number of metabolically active cells on the scaffolds were quantitatively 
assessed using the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt (MTS, Promega, 
CellTiter96® AQueous Solution Cell Proliferation Assay 
117,118. The MTS cell proliferation is a 
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colorimetric assay that measures the reduction of the tetrazolium compound by the cells into 
a coloured formazan product that is soluble in tissue culture media. The amount of formazan 
produced, as a measured by the absorbance, is directly proportional to the number of living 
cells in culture. The seeded scaffolds cultured were transferred to a new 24-well tissue 
culture plate. Then 1 ml of culture medium that had already been warmed to 37oC was added 
to each sample. 200 µl of MTS solution, thawed for 10 min in a water bath at 37oC, were 
added to each well. The samples were incubated over 3 h at 37oC and 5%CO2. The 
absorbance of the produced formazan was recorded at 490 nm using a 96-well plate reader 
(Elx 808, Ultra Microplate Reader, Bio-TEK Instruments, Inc., Bath, UK). The statistical 
significance between sets of data was calculated using ANOVA (one-way). Data were 
considered significant when p value of 0.05 or less was obtained (showing a 95% confidence 
limit).  
4.4.3 Scanning Electron Microscopy 
Following cultivation of the leukemic cell lines on the scaffolds for different periods of 
time, the scaffolds were examined by SEM (JEOL JSM-840A, JEOL Ltd., Welwyn Garden 
City, U.K.); after removing from the media, the scaffolds (containing cells) were fixed with 
2.5% PBS-buffered glutaraldehyde solution (Fluka BioChemika, Switzerland) for 40 min at 
4oC and washed twice with PBS. They were then dehydrated in a graded series of ethanol 
(50, 70, 90, 95, and 100%), each for 5 min and the samples were dried in an aseptic 
environment for 4 h. The specimens were sectioned and then sputter-coated with gold in 





 For each condition, two samples of each scaffold, PLGA and PU, were harvested and 
fixed in 2.5% PBS-buffered glutaraldehyde solution as described in section 3.4.3. and then 
embedded with a xylene replacement (Paraclear™ ; Polyscience Inc, Warrington, PA), and 
sectioned at 8 µm thickness using a Shandon Finesse® ME  Microtome (Shandon, Pittsburgh, 
Pennsylvania, USA). Xylene was not used due to the incompatibility of its components with 
the polymeric scaffolds, which in the initial studies lead to the dissolution of the scaffold. 
Instead, Paraclear (Polyscience Inc, Warrington, PA), a xylene replacement was used.  After 
dewaxing, cell-polymer slides were immersed for 30 s in Haematoxylin (Sigma-Aldrich), 
then rinsed with tap water and counterstained with 1% Eosin (Sigma-Aldrich) for 2min.  
4.4.5 Flowcytometry 
Cultured cells were analysed for phenotypic expression of surface proteins specific for 
subpopulations of hematopoietic cells. Cells were stained with monoclonal antibodies 
(mAbs) conjugated to either phycoerythrin (PE) (anti-human-CD71; BD Bioscience) to 
assess T and B lymphocytes, fluorescein isothiocynate (FITC) (anti-human-CD45; BD 
Bioscience ) to assess leukocytes or phycoerythrin (Pc5) (anti-human-CD38; Beckman 
Coulter, USA) to assess early differentiated cells. Eppendorf tubes containing the cultured 
cells in a concentration of 0.2-1x106 cells in 1 ml were washed once in 2% FBS in PBS with 
0.1% sodium azide (staining buffer) and then stained with various combinations of 
fluorescently conjugated monoclonal antibodies. The cells were incubated at 4oC in the dark 
for 30 min. Following one wash with the staining buffer, cells were fixed with 2% (v/v) of 
Paraformaldehyde (BDH Industries Ltd, India) and analysed by flowcytometry within 24 h. 
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Alignment and calibration of fluorescence detectors were performed using Fluorosphere/ 
Flow-check beads (Flow-Check™, Beckman Coulter, Ireland). Respective isotypic controls 
were also used for each flourochrome, PE, FITC and Pc5. 30,000 events were acquired for 
each sample at different time intervals in a list mode file format. The analysis was made 
using a FACS flowcytometer (Beckman Coulter) and WinList 5.0 software (Verity Software 
House). Dead cells were gated out during data analysis. 
4.4.6 Colony Forming Assay 
The CFU assay has been developed to quantify multi-potential progenitors and lineage-
restricted progenitors of the erythrocyte, granulocyte, monocyte-macrophage, and 
megakaryocyte myeloid cell lineages. Cells were extracted from the scaffolds after 
centrifugation and were inoculated in MethoCult® (StemCell Technologies, USA) at 2.5-
7.5x105 per ml in duplicate polystyrene 35 mm petri dishes (Corning®, The Netherlands). 
The dishes were incubated at 37 oC and 5% CO2 for 14 d, after which the number of colonies 
was determined by manual counting. CFU, BFU, GM and GEMM were scored according to 
colour and morphology with the inverted microscope (Leica DM microscope, Milton Keynes, 
UK). 2 replicates were counted for each sample. Blindly reproducibility was ensured and 
compared by other members of the laboratory.  
4.4.7 DNA Quantification 
 Total DNA content was measured using Quant-iT PicoGreen dsDNA Reagent Kit 
(Invitrogen, UK), as an indirect method of evaluating the increase in cell number. Scaffolds 
were removed from culture and placed in an eppendorf tube where they were digested in 1ml 
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of 50 ug/ml proteinase-K (Sigma-Aldrich) in 100 mM dibasic potassium phosphate solution, 
pH 8.0 (K2HPO4; Sigma-Aldrich) overnight at 37oC. Proteinase-K was then inactivated at 90 
oC for 10 minutes. Following cooling of the sample to ambient temperature, 50 µl were 
placed in a DNA/RNA 96 well-plate along with 50 µl of PicoGreen reagent which had been 
diluted in 10 mM TE buffer (Tris-HCl, 1 mM EDTA, pH 7.5) based on DNase-free water and 
vortexed for 2-3 minutes. 50 µl aliquots of the solution were then read using a fluorometer 
(MFX microplate fluorometer; Dynex technologies, West Sussex, UK) with the excitation 
wavelength being at 480 nm and the emission wavelength at 520 nm. The amount of total 
DNA produced from the CB MNC cultured was enumerated as an absorbance value in order 
to calibrate the number of cells per sample based on a DNA content curve.  
4.4.8 Statistical analysis 
The experiments evaluating the 3 cell line cultures for each of the 6 different polymers 
were done on 3 different occasions, in triplicate on each occasion. The long-term culture 
experiments (over 8 weeks) on PLGA and PU were done in triplicate on 2 separate occasions 
(N=2) and representative data are provided. Statistical significance of the results was 
evaluated by using one-way analysis of variance (ANOVA) with a level of p<0.05 or p<0.01 
depending on the measure considered significant. Data were analyzed by linear regression 













 Tissue engineering is “an interdisciplinary field that applies the principles of 
engineering and the life sciences toward the development of biological substitutes that 
restore, maintain, or improve tissue function” 119. Tissue Engineering has three basic 
components: cells (cell type varies depending on the required tissue target), scaffolds and 
bioprocessing (involving bioreactors and biosignals). The principle is based on the fact that 
as the cells begin to attach, proliferate, and develop in the 3-D scaffold, they would start 
secreting their own ECM, and then the tissue would be vascularised, the scaffold would 
degrade and the degradation by-products would be eliminated by the body 120.  
In order to develop a suitable ex vivo mimicry for the study of AML, three AML cell 
lines were employed and tested on a variety of scaffolds. The design of an appropriate 
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scaffold able to support cellular growth that mimics natural niches is extremely important in 
Tissue Engineering. In general an ideal scaffold should be:  
 Biocompatible: the scaffold and its by-products should not induce toxicity and the 
biodegradability must be controlled. 
 Highly Porous with good pore interconnectivity to provide enough space for cell 
adhesion, migration, proliferation, ECM production and nutrient diffusion. 
 Mechanical strength to maintain a defined 3D structure. 
 High surface area per volume ratio. 
 Reproducible fabrication. 
Natural and synthetic polymers are among the most common biomaterials used to 
fabricate 3-D scaffolds. Natural derived materials include: collagen, glycosaminoglycans, 
polypeptides, etc. One of the limitations of natural scaffolds is their weak mechanical 
properties and enzymatic degradation, which restricts their wide use 121. In contrast, the use 
of synthetic polymers has been expanded; in particular the use of biodegradable poly(α-
hydroxyesters) for in vitro applications and non-biodegradable polymers for clinical 
orthopedic applications in filling bone defects and providing mechanical stability 122. 
Important advantages in biomaterials have led to an increasing interest in polymers that 
mimic the in vivo environment by providing the required architecture, structural properties, 
and the necessary biosignals. The polymers must meet minimum requirements essential for 
their application in biomedicine because they are always in direct contact with living cells, 
which are very sensitive to their immediate environment. As a starting point in scaffold 
design, three main characteristics should be considered: non-toxic to the cells, sterilisable and 
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biocompatible. Once these considerations have been addressed, then other issues such as 
surface area, porosity, pore size should be tackled in order to improve cell adhesion, 
spreading, proliferation and differentiation 123. Furthermore, synthetic polymers are amenable 
to customisation and design, as well as reproducible fabrication and large-scale production 
124.  
5.2 AIM AND HYPOTHESIS  
 This investigation was based on the hypothesis that 3-D growth configuration for 
AML expansion will simulate the in vivo marrow environment more faithfully than 2-D 
culture, resulting in an enhanced in vitro culture without the need to add exogenous 
cytokines. In order to do so, six polymeric scaffolds were selected for their properties and 
tested as suitable materials for AML seeding and growth. The ideal scaffold should have the 
following properties:  
 Pore size <100µm and high pore interconnectivity to allow cell penetration and 
aid nutrient distribution throughout the scaffold. 
 Porosity of 80-95%. 
 God mechanical strength. 
 Non-toxic for the cells and should support cell proliferation. 
5.3 APPROACH TO STUDY 
 Six different synthetic polymers fabricated in our laboratory using the thermally 
induced phase separation (TIPS) process were used; all FDA-approved for biologic and 
biomedical engineering applications 125-129 but all with different properties such that the 
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behavior of the cells when in contact with the polymers could vary. The selection of the 
polymers was made on the basis of previous research carried out in our laboratory 130. The six 
polymers selected fulfilled the properties stated at the beginning of the investigation related 
to porosity, pore size/interconnection, etc. and the fact that all the polymers had very 
different structures made them ideal for the research. Scaffold characterisation was carried 
out in a previous project in our laboratory130 and the results were used in this investigation. 
Table 5.1: List of Synthetic Polymeric Scaffolds used in the investigation showing also some 
relevant properties. The list groups the synthetic polymers into two different categories: 
biodegradable and non-biodegradable. 







250,000 93.5 KPa 
Poly(D,L-lactide) 
(PDLLA) 
250,000 1.29 MPa 
BIODEGRADABLE 
Polycaprolactone (PCL) 66,000 120 Mpa 
Polystyrene (PS) 250,000 3 GPa 
Poly(methyl 
methacrylate) (PMMA) 
77,000 2 GPa NON-BIODEGRADABLE 
Polyurethane (PU) 125,000 17.5 KPa 
 
 
The above scaffolds were fabricated in our lab and the results were compared with 
commercially available scaffolds that showed similar properties. These commercially 
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available scaffolds were obtained from BD™ Bioscience and were selected because they 
were suitable for short- and long-term growth and differentiation of a variety of cell types, 
including: epithelial cells, neurons, endothelial cells, osteoblasts, chondrocytes, fibroblasts, 
and smooth muscle cells 131-133. BD™ Bioscience claims that the 3-D scaffolds they produce 
mimic the in vivo environment to induce tissue formation or promote tissue repair.  
Two different types of scaffolds were tested from BD™ Bioscience: the BD™ 3D 
Collagen Composite scaffold and the BD™ 3D OPLA® scaffold. 
5.4 RESULTS 
Synthetic polymeric scaffolds, as previously stated, were fabricated using the thermally 
induce phase separation (TIPS) technique. This technique uses thermal energy as a latent 
solvent to induce phase separation into polymer-rich and polymer-lean phases. Subsequently, 
the polymer solution is quenched below the freezing point of the solvent and then freeze 
dried to produce a porous structure 116. Various porous structures can be obtained by 
adjusting different thermodynamic and kinetic parameters. The TIPS technique has been 
previously reported to be used to produce scaffolds for tissue engineering applications, such 
as biodegradable polylactide foams 134,135 or polyurethane foams for the reconstruction of 
meniscus lesions 136,137.  
  The surface structure of the scaffolds was studied using a scanning electron microscope; 
parameters such as specific pore volume (Vp), envelope density (ρe), and percentage porosity 
(P) of the scaffolds were obtained using pycnometry (Geopyc® 1360 V1.03, Micromeritics).  























The mass (g), the volume V (cm3) and the bulk density ρb (g/cm3) of each sample were 
measured. 
Table 5.2: Properties of scaffolds used in this investigation. 



















PLGA is a copolymer formed by poly(glycolic acid) (PGA) and poly(lactic acid) (PLA) 
and offers many advantages including good mechanical strength, low toxicity, 
biocompatibility (FDA approval), and controlled biodegradability. Degradation can be 
controlled by varying the monomer ratio of glycolic and lactic acids 124. PLA is more 
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hydrophobic than PGA, therefore PLA-rich PLGA copolymers are less hydrophilic and 
consequently absorb less water degrading slower. When the ratio is 50:50 (in this study the 
ratio was 43:57), PLGA is hydrolysed much more rapidly than those containing higher 
proportion of either of the two monomers 138. There are no cell recognition sites on the 
surface of this type of polylactone polymer which can affect cell affinity 118; by pre-wetting 
the scaffold with ethanol its hydrophilicity could be improved 118,139.  
PLGA has been successful as a biodegradable polymer because it undergoes hydrolysis in 
the body to produce the original monomers, lactic acid and glycolic acid. These two 
monomers, under normal physiological conditions, are by-products of various metabolic 
pathways in the body. Since the body effectively deals with the two monomers, there is 
minimal systemic toxicity associated with using PLGA for drug delivery or for tissue 
engineering applications. Examples of PLGA use in tissue engineering include the expansion 
of human foreskin fibroblasts 140, chondrocytes 141 and osteoblastic cells that expressed 






Figure 5.1: Scanning Electron Microscopy of PLGA. The SEM shows PLGA at a resolution 





 PLGA quenching temperature was set at -196oC; it is 90.1±1.30 % porous; its 
architecture is characterised by a combination of interconnected micro-pores in the range of 
50-100 µm and macro-pores exceeding 200 µm; it has a sponge-like structure and is rigid. 
 
5.4.2 Poly(D,L-lactide) 
 Poly-D,L-lactic acid (PDLLA) is a well-known super-high molecular-weight acid that 
has good biocompatibility and degrades following in vivo implantation 143. It has been 
previously shown that PDLLA, alone or as a composite, supports the growth of osteoblasts, 
chrondrocytes, and lung carcinoma cells 144. These features, plus the intrinsic adequate elastic 









Figure 5.2: Scanning Electron Microscopy of PDLLA. The two phases of the polymer are 
present in this SEM micrograph. The resolution of the picture is of 500 µm. 
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 The SEM micrographs highlight the open and interconnected pore structure of PDLLA. 
The scaffold has a ladder-like structure following the freezing direction of the polymer 
solution. PDLLA is a very porous scaffold with a porosity of 98.2±1.24 %; has a sponge-like 
structure, and is rigid.  
5.4.3 Polycaprolactone 
 Polycaprolactone (PCL) is a biodegradable polymer with a low melting point of 
around 60°C. PCL is an aliphatic polyester with semi-crystalline properties and is highly 
water soluble resistant 145. It is degraded by hydrolysis of its ester linkages in physiological 
conditions into a byproduct of caproic acid. PCL has been used for the preparation of long-
term implantable devices, due to its degradation which is even slower than that of polylactide 
and can persist in vivo for up to 2 years 146. PCL has been used to support growth of 







Figure 5.3: Scanning Electron Microscopy of PCL.  
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 PCL presents a combination of micro-pores of 20-50 µm and macro-pores of 100 µm but 




 Polystyrene (PS) is an aromatic polymer made from the aromatic monomer styrene, a 
liquid hydrocarbon that is commercially manufactured from petroleum by the chemical 
industry and also used in tissue culture plastics 149. PS is non-biodegradable and has a very 
homogenous structure in a honey-comb like structure. It has a porosity of 82.5±0.75 % and is 









Figure 5.4: Scanning Electron Microscopy of PS. The micrograph shows pores of similar 
size and well distributed at a resolution of 500 µm. 
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5.4.5 Poly(methyl methacrylate) 
 Poly(methyl methacrylate) is a thermoplastic non-biodegradable polymer with a good 
degree of biocompatibility with human tissue. It has been used for replacement intraocular 
lenses when the original lens has been removed as part of the treatment of cataracts. In 








Figure 5.5: Scanning Electron Microscopy of PMMA. The resolution of the micrograph is of 
500 µm. 
  
 PMMA scaffolds are rigid with a non-homogenous structure. The porosity was measured 
to be of 94.0±1.36 % and the pore size of ≥80 µm.  
5.4.6 Polyurethane 
 Polyurethane is a non-biodegradable polymer consisting of a chain of organic units joined 
by urethane links. Polyurethane is prepared by reacting diisocyanates with diols; the 
diisocyanates react with water to form a disubstituted urea and carbon dioxide gas which acts 
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as a blowing agent. This water reaction is exploited commercially to manufacture flexible 
and rigid polyurethane foams. 
 PU produced using the solvent casting/salt leaching technique has been used as a porous 
scaffold for knee-joint meniscus applications 151; Zhang et al created a porous scaffold with 
controlled pore size distribution to support the growth and proliferation of rabbit bone 
marrow stromal cells 152; it has also been utilised as a cardiovascular biomaterial or as a long-








Figure 5.6: Scanning Electron Microscopy of PU. The resolution of the micrograph is of 100 
µm; from this picture it can be appreciated the homogeneous pore arrangement and size 
 
 PU has a honey-comb structure; its pore distribution is very homogenous with well 




5.4.7 BD™ 3D Scaffolds 
The BD™ 3D OPLA® (Open-Cell Polylactic Acid) scaffold is a synthetic polymer 
scaffold that is synthesised from D,D-L,L polylactic acid. This material has facetted 







Figure 5.7: Scanning Electron Microscopy of BD™ 3D OPLA®.  This SEM micrograph 
shows the architecture of OPLA at 1 mm resolution. 
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The BD collagen composite is a natural scaffold formed from a mixture of collagens that 
are derived from bovine hide. Overall, this material exhibits collagen fibrillar architecture, 







Figure 5.8: Scanning Electron Microscopy of BD™ 3D Collagen Composite.  This SEM 
micrograph shows the architecture of OPLA at 500 µm resolution. 
  
5.5 DISCUSSION 
 Synthetic polymers represent a novel and promising material to be used in tissue 
engineering. The polymers selected for testing in this thesis fulfill the important properties 
that all the scaffolds used for biomedical applications should have. They are biocompatible, 
highly porous, possess mechanical strength, have a high surface area per volume ratio and are 
reproducible for fabrication. Additionally, the polymer properties can be adjusted easily by 
just varying the molecular weight of the polymer, hence obtaining a porosity and pore size 
similar to the tissue or organ that wants to be mimicked 116. The TIPS technique chosen to 
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fabricate the polymers included the dissolution of the polymer in the appropriate solvent and 
the subsequent freezing. The frozen polymer was then freeze-dried under reduce pressure 
creating the pores in the scaffold which are aligned in the direction of the freezing. Other 
methods use to fabricate highly porous scaffolds include fiber bonding, solvent 
casting/particulate leaching and gas foaming. The benefit of using the fiber bonding 
technique is the possibility to produce porous scaffolds with interconnected pores suitable for 
tissue regeneration 139. The disadvantage is the toxicity of the organic solvents used to 
dissolve the polymer and the need of using extreme temperatures in the fabrication process 
156. 
The solvent casting/particulate leaching method also includes the use of organic solvents 
and involves the mixing of water-soluble particles into a biodegradable polymer/solvent 
solution. After the mixture is casted into a container, the solvent is evaporated by drying. The 
particles are then leached out by a suitable solvent resulting in a porous polymer film or 
scaffold. The advantage of this method is the wide range of porosity and pore sizes that can 
be created just by changing the particle size as well as its simplicity 157. However, the 
disadvantages are the preparation time needed, which is considerably higher than other 
methods due to the leaching step, the not fully interconnected pores, and the variation of the 
pore size due to poor dispersion 158. Currently, the problem of the not-interconnected pores 
has been investigated and resolved 159 but the issue of using organic solvents remains. 
Another promising technique that does not require the use of organic solvents is the gas 
foaming approach that utilises high-pressure CO2 for equilibrating compressed polymers into 
solid discs followed by a sudden decompression to ambient levels leading to the formation of 
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the pores 160,161. The advantage of this method is the elimination of the use of organic 
solvents but on the other hand, the disadvantages include the largely unconnected pores, 
especially on the surface of the foam,  and the high temperatures needed for the disc 
formation, making it difficult to incorporate cells in the scaffold or to impregnate with other 
molecules, such as collagen 139. Harris et al. 162 combined the particulate leaching and gas 
foaming techniques to create 3-D PLGA porous scaffolds without using organic solvents. 
Finally, other methods used to fabricate 3-D prototypes that mimic the microstructure of 
living tissue include rapid phototyping (RP) or solid freeform fabrication (SFF). The 
limitations of these techniques are the low resolution achieved so far and the small number of 
materials that can be used with these methods 145.  
After considering various techniques to produce scaffolds with a pore size and porosity 
that could be controlled, the TIPS method was thought to be the best option, and scaffolds 
with large porosities (up to 90%) and pore size of approximately 100 µm were produced. 
Even though TIPS also employs organic solvents, which can be toxic to cells, the flexibility 
in the design parameters that it offered rendered it a most convenient technique to produce 
scaffolds. The porosity and mechanical properties can be varied by adjusting the polymer 
concentration and the pore structure is controlled by the quenching temperature 116. 
As previously stated, the aim of this chapter was to create scaffolds that mimicked the 3-
D structure of the bone marrow. As the BM is a highly organised and complex structure and 
contains hematopoietic cells and supporting stroma, the new 3-D structure should be a 
network of interconnected pores in the range of 100 µm. Interconnected pores are required in 
order to supply nutrients and oxygen and remove metabolites as well as to promote cell 
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migration and aggregation. The highly porous configuration will allow cell penetration 
throughout the scaffold.  
The 6 scaffolds under study in this thesis were of two types: biodegradable and non-
biodegradable. The non-biodegradable scaffolds were PU, PMMA and PS, which have been 
extensively used in tissue engineering primarily because they are biocompatible; although 
there is some evidence of limited enzymatic degradation of PU that can cause toxicity 163. 
Initial uses of PU as a biomedical material, resulted in acute allergic reactions when 
implanted, which were mainly caused by using impure material. The problem has been 
resolved by using segmented polyester urethanes, which are more stable and lack 
susceptibility to hydrolysis. Nowadays polyurethanes are the preferred polymer to be used for 
blood contacting devices. Commercial examples include: Biomer®, Pellethane® and 
Tecoflex®. PMMA in set forms is used as hard contact lenses and as a bone replacement in 
joint replacement surgery 164. PS was chosen because it is broadly used in tissue culture 
plastic and is considered de “golden standard”. 
In addition to the non-biodegradable scaffolds, biodegradable scaffolds were also 
fabricated and compared. PLGA, PDLLA and PCL are highly porous, biocompatible, have 
mechanical strength, a high surface area per volume ratio and are reproducible for 
fabrication. The problem that all the biodegradable polymers have is the decrease of 
mechanical strength with time. The mechanical properties of the polymer are proportionate to 
the square root of the molecular weight and therefore decreases very rapidly as the polymer 
degrades 165. Nevertheless, as the scaffolds in this investigation were tested for periods of no 
longer than 10 weeks, the degradation of the polymers was not an issue. 
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As it can be seen for the SEM micrographs, these polymers although all have a synthetic 
origin, they all produced very different scaffolds even if the method used for production was 
the same. The first scaffold studied was PLGA, which has a structure formed by a 
heterogeneous mixture of micro a macro pores; this scaffold seamed ideal for AML cell 
culture because the cells could be seeded and penetrate easily thought the large pores.  
PDLLA was considered for the study has it is a very porous scaffold; its structure is formed 
by a two phase configuration arranged in a ladder-like form orientated towards the freezing 
direction of the polymer, making it a suitable scaffold to study for cellular expansion. 
Polystyrene was also studied as a possible material for this investigation and the results 
showed a homogenous pore distribution with pore sizes ranging from 50 to 100 µm and a 
rigid scaffold appropriate for tissue engineering. PMMA presented a non-homogeneous 
structure with 80 µm pores, although the standard minimum pore size for tissue engineering 
is of 100 µm, the use of PMMA was considered and compared with the rest due the fact that 
is a widely used polymer and presented a high porosity.  PU on the other hand, showed a very 
homogenous pore distribution and a high porosity making it an ideal scaffold for cellular 
seeding; PU resulted in a flexible scaffold whish differs from the rest of the scaffolds 
produced whish were all rigid. PU has a honey-comb structure with pores of 60-120 µm. 
Sterilisation was studied following the methods proposed by Shearer et al which 
described sterilisation methods for PLGA flat sheet and hollow fiber 166. The scaffolds 
selected for this study were subjected to numerous tests until an optimal sterilisation method 
was performed, which included a combination of ethanol and ultraviolet irradiation and the 
addition of Penicillin / Streptomycin to the culture medium.  The sterilisation methods 
 91 
 
studied included different time intervals under UV irradiation and a subsequent surface 
analysis performed by SEM. 
As a result, all the scaffolds produced followed the golden guidelines of the ideal scaffold 
when designed for tissue engineering. They are all highly porous, with scaffolds going from 
65-98% porosity. The interconnectivity of the pores can be seen from the SEMs pictures 
analysed; PU and its honey-comb structure is ideal for cell seeding, with uniformly 
distributed pores ranging from 60-120 µm. The structure of PS is very similar to PU although 
is a non-compressible scaffold therefore should be handled with care when manipulating it. 
PLGA, PDLLA and PCL have a different structure, where the micro and macro pores are 
combined. Overall, all the scaffolds, apart from PCL, fabricated had the porosity needed for 
successful cell seeding, and the pore interconnection that would aid cell migration. PCL had a 
porosity of 68% which is low for a scaffold that is going to be used in tissue engineering but 
even if the porosity was low, the six scaffolds fabricated were tested by seeding them with 
AML cells and the results are presented in chapter 6.  
5.6 CONCLUSION 
 The mechanical properties of synthetic scaffolds are very important factors that need to be 
studied and characterised when designing a scaffold for tissue engineering. In this chapter, 6 
different scaffolds were fabricated and characterised in our laboratory and their properties 
were summarised in table 5.2.; these scaffolds were compared with two commercially 
available scaffolds from BD™ Biosciences produced from similar materials and displaying 
similar properties. Overall, the 6 scaffolds created possessed the properties listed in the 
introduction regarding the ideal scaffold. They are all biocompatible, highly porous, have 
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mechanical strength, high surface are per volume ratio and are reproducible for fabrication.  
The next step in this investigation was to test their compatibility and affinity with AML cell 
























 Bone marrow is a complex 3-D tissue wherein hematopoiesis is regulated by spatially 
arranged cellular microenvironments (niches). The dysregulation of the niches, either in 
structure or function, is implicated in the pathogenesis of disease states of the bone marrow, 
such as leukemia 167. Not only is the spatial arrangement of stem cell niches destroyed, but an 
increase in fibrosis and neoangiogenesis is also a prominent feature in the leukemic bone 
marrow microenvironment 42.  Although 2-D in vitro cultures and in vivo animal models of 
AML have helped to elucidate the molecular determinants of leukemogenesis, the cellular 
and micro-environmental elements integral to this process are difficult to decipher based on 
the limitations of these same techniques. As presented in Chapter 5, six different scaffolds 
were developed based on the hypothesis that a 3-D growth configuration will simulate the in 
vivo marrow environment more faithfully resulting in enhanced (more physiologically 
accurate) in vitro cultures without the addition of exogenous GFs. Consequently, such an ex 
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vivo mimicry of leukomogenesis could be used to develop and investigate novel treatment 
strategies (chemotherapeutic, immunologic, and targeted), possibly replacing some of the 
current animal models. 
Since the architecture as well as the surface properties of different scaffolds affects cell 
attachment, adhesion, growth and differentiation, initial studies on scaffold selection were 
conducted. Although AML cell lines are already cytokine-independent in 2-D static culture, 
this primary study of cell lines in 3-D focusing on the material and physical culture required 
by AML cells clarified the environmental needs of the primary cells as well. As primary 
AML is a heterogeneous disease, the system was designed for the culture of different AML 
cell lines. 
As a result, three different AML cell lines were tested: K-562, HL-60 and Kasumi-6 and 
seeded onto the 6 scaffolds previously described in Chapter 5: PLGA, PDLLA, PS, PCL, 
PMMA and PU. The results and a brief discussion are presented firstly by introducing the 
properties of the cell lines used; then by presenting the seeding efficiencies and the cell 
proliferation of the six scaffolds seeded with the AML cell lines; followed by a more detailed 
study on the two finally selected scaffolds. Chapter 6 finishes with a comparison of the 
scaffolds fabricated in the laboratory with two commercially available scaffolds from BD™ 
Biosciences. 
6.1.1 Leukemic cell lines 
 Given that the first human continuous cell line was established in 1963, several 
hundreds of cell lines have been derived from patients with leukemia 168 from all 
hematopoietic cell lineages. Leukemic cell lines are essential for the study of the progression 
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of the disease and provided several culture advantages over primary leukemic cells in the 
initial stage of my research thesis. The major advantages and the reason why the use of cell 
lines was chosen are as follows: 
− They originate from the same cell, monoclonal origin. 
− The differentiation is arrested at a determined maturation stage. 
− Genetic alterations. 
− Sustained proliferation in culture. 
Table 6.1 shows the comparison and the main properties of the 3 cell lines selected: 
origin, year of establishment and culture medium used to expand them, etc. The cell lines 
differ in their origin, and that is the reason why they were chosen, in order to study a more 
heterogeneous set of results. The HL-60 is a promyelocytic leukemia cell line, the K-562 line 
is composed of undifferentiated blast cells that are rich in glycophorin and Kasumi-6 is a 
myeloid leukemia cell line 169. In general and under optimal culture conditions, this cell lines 
retain most of the major features of their original cells 170.  
Table 6.1: Acute Myeloid Leukemia cell lines properties. The table summarises the main 




HL-60 171 K562 172 Kasumi-6 173 
Cell phenotype Myelocytic cell Erythroblast cell Myeloid cell 







Source of material Peripheral blood Bone marrow Peripheral blood 
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Year of establishment 1976 1975 1999 
Culture Medium 
80% IMDM + 20% 
FBS 
90% IMDM + 10% 
FBS 
80% RPMI 1640 + 
20% FBS + 2ng/ml 
GM-CSF 
Sub-cultivation routine 
Maintain at 0.1-1 x 
106 cells/ml. 
Renew media 
every 2-3 days. 
Maintain at 0.1-1 x 
106 cells/ml. 
Renew media every 
2 days. 
Maintain at 0.2 -
1.5 x 106 cells/ml. 
Renew media 
every 2-3 days. 
Doubling time 36 - 48 h 12 -18 h 55 h 
In situ morphology 8 µm 10 µm 7 µm 
 
 
6.2 AIM AND HYPOTHESIS  
  It was hypothesised that by using a 3-D culture system that resembled the highly 
porous structure of the bone marrow, a good representation of the original leukemic bone 
marrow architecture will be reproduced. Leukemic cell culture could be maintained with its 
original phenotypic features, independent of cytokine addition, and the natural AML growth 
expansion could be studied in its natural state ex vivo. 
 
6.3 APPROACH TO STUDY 
The general approach to this study was to seed the 6 scaffolds fabricated and 
characterised in chapter 5, with the 3 AML cell lines presented in the introduction of this 
chapter. The scaffolds were evaluated in terms of seeding efficiency, which was measured 24 
h after seeding, and cellular proliferation using the MTS assays at different time intervals of: 
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48 h, 1, 2, 3, and 4 weeks. Once the best scaffolds suitable for AML expansion were 
indentified, long-term culture tests were performed on the selected ones. Finally the results 
obtained were compared with those from the commercially available scaffolds and a 
conclusion of the most suitable scaffold was outlined.   
 
6.4 RESULTS 
6.4.1 Seeding Efficiency 
 The seeding efficiency shows the percentage of cells that remained in the scaffold after 
24 h of seeding. It can be seen that PCL and PS had a very low seeding efficiency, meaning 
that less than 20% of the cells seeded remained in the scaffold; this can be caused by the 
structure of the polymers and by their high hydrophobicity. On the other hand, the seeding 
efficiency of PLGA, PMMA, PU and PDLLA was above 60% and in some cases of above 





























Figure 6.1: Seeding efficiency of the six polymers seeded with K-562, HL-60 and Kasumi-6. 
The graph shows the number of cells as a percentage of the cells remaining in the scaffold 
after 24 h. N = 3. 
 
 Seeding efficiency of PS and PCL was found to be statistically lower (p<0.05) than 
PLGA, PMMA, PU and PDLLA. 
6.4.2 Cell Proliferation 
 Cellular proliferation of the three cell lines seeded onto the scaffolds was measured using 
the MTS assay over a period of 4 weeks. Out of the 6 bio-compatible scaffolds evaluated, 




































lines consistently. Figure 6.2 (a, b and c) illustrates metabolically active cells in relation to 












Figure 6.2(a): Cellular proliferation of HL-60 when seeded on the 6 different scaffolds. The 
MTS assay gives a measure of cellular proliferation in relation to the absorbance. In this case 
it can be seen that HL-60 grows best when seeded onto PU and PLGA. N = 3 
 
 Figure 6.2(a) shows the cellular proliferation of HL-60 when seeded on the six scaffolds; 
from the graph it can be seen the statistically higher absorbance values (p<0.05) obtained 
when the cells were seeded on PU and PLGA. After 4 weeks in culture only these two 
polymers maintained cellular growth. PCL, PMMA, PS and PDLLA maintained cellular 














































Figure 6.2(b): Cellular proliferation of K-562 when seeded onto the 6 different scaffolds. 
The MTS assay shows a similar behaviour of this cell line when seeding it onto PLGA and 
PU. N = 3. 
 
 Figure 6.2(b) shows cellular proliferation of the K-562 cell line. From the graph it can be 
seen the statistically higher (p<0.05) values of absorbance reached when the cells were 
seeded on PU and PLGA. These results are comparable to figure 6.2(a) although in this case 
the absorbance values are higher. The difference in absorbance can be appreciated from week 























































Figure 6.2(c): Cellular proliferation of Kasumi-6 when seeded onto the 6 different scaffolds. 
Kasumi-6 similarly than the other two cell lines proliferates more in PU and PLGA than in 
any of the other four scaffolds. N = 3. 
 
 Figure 6.2(c) represents the cellular proliferation of Kasumi-6 seeded on the six 
polymers. In this case the absorbance values are lower than when using the other two cell 
lines; proliferation was statically higher (p<0.05) at week 4 when seeded on PLGA and PU. 
 Overall, it can be observed the statistically higher results obtained by PLGA and PU 
when compared with the other scaffolds. Thus, due to the promising results showed when 
seeding PLGA and PU with AML cell lines, it was decided to continue with a further 





biodegradable respectively, giving a chance to study both characteristics. The next step was 
to perform long-term culture studies on these two scaffolds that lasted for 8 weeks. 
 
6.4.3 PU and PLGA long-term Culture Studies 
All three AML cell lines were assessed for establishment of the culture, maintenance of 
cell growth and cellular activity on each of the 2 scaffolds selected over a period of 8 weeks. 
Since K-562 has a known doubling time of 12 h, three times higher than that of either 
Kasumi-6 or HL-60 169, a difference in growth kinetics over the first 48 hours was expected 
when compared with the other 2 cell lines when cultivated on either PU or PLGA (Figures 
6.3 (a) and (b)). Both scaffolds with K-562 cells showed a statistically significant higher 
absorbance (i.e., metabolic activity of cells) over all weeks of culture (p<0.01), compared 
with that of the other two cell lines; this absorbance stabilised after 1 week, although another 
small peak of activity in both the PU and PLGA scaffolds was observed at weeks 6 and 5, 
respectively. In contrast, the Kasumi-6 and HL-60 cell lines exhibited a slower increase in 
metabolic activity, peaking at 4-5 weeks. The absorbance values follow a similar AML-cell-
line-specific pattern of cellular activity in both PU and PLGA (Figures 6.3 (a) and (b)), 
































Figure 6.3(a): Long term cellular proliferation studies of K-562, HL-60 and Kasumi-6 
seeded onto PU. The curved line shows the growth trend of the three cell lines. N = 3. 
 
 Regression analysis shows the three growth trends that the different cells lines followed. 
K-562 as it has a faster growing time, establishing as a culture faster than the other two cell 
lines. HL-60 and Kasumi-6 displayed a similar trend although Kasumi-6 was slower due to 
the fact that this cell line still needs the addition of growth factors to survive. In the same way 
than in the case of PU, when using PLGA the growth trends were comparable. K-562 
established as a culture faster than the other two cell lines and Kasumi-6 although had a 
similar trend than HL-60 it was slower due to the delicacy of the cell line. 
Time (weeks) 





















































Figure 6.3(b): Long term cellular proliferation studies of K-562, HL-60 and Kasumi-6 
seeded onto PLGA. The curved line shows the growth trend of the three cell lines. N = 3. 
 
 
6.4.4 Comparison with commercially available scaffolds 
BD™ Biosciences 3D scaffolds were used in the investigation and the results were 
compared with those obtained from the scaffolds made in our laboratory. Two types of 
commercially available scaffolds were tested: BD™ 3D OPLA®, and BD™ 3D Collagen 
Composite. The OPLA (Open-Cell Polylactic Acid) is a polymer synthesised from D,D-L,L 
polylactic acid; and the Collagen Composite is a natural scaffold from a mixture of collagens 
(type I and III) derived from bovine hide.  The seeding efficiency and seeding methods were 
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performed following the same methodology previously used for the initial scaffold 
evaluation.  
Figure 6.4 shows the comparison of the two commercial available scaffolds vs. PLGA 
and PU; it demonstrated a statistically significant higher efficiency (p<0.05) of PU compared 
with the OPLA scaffold. Overall the seeding efficiency of the 2 commercially available 
scaffolds is lower than the 2 polymers produced and tested in our lab. As a result it can be 
confirmed that AML cell lines had a better affinity when seeded onto PU and PLGA and 






















Figure 6.4: Comparison of the seeding efficiencies of commercially available scaffolds from 
BD™ Biosciences 3D vs. PLGA and PU. PU seeding efficiency is statistically higher (p< 















































Cellular proliferation was determined using the MTS assay which measures cellular 
activity in relation to the absorbance. Figure 6.5 describes the cellular proliferation of the 
different cell lines when seeded onto the 2 commercial available scaffolds from BD™ 
Biosciences compared to PLGA and PU. The study follows an 8 week period where the 
collagen composite scaffold degraded (in two studies: HL-60 and Kasumi-6) before the study 
was over. OPLA had a statistically significant higher proliferation when compared to PLGA. 
At the early stages the absorbance was higher in the BD™ Biosciences scaffolds (p< 0.05) 
but as the study progressed and one of the commercially available scaffolds tested degraded, 






















Figure 6.5(a): Cellular Proliferation of HL-60 seeded onto OPLA, Collagen Composite, 



















































Figure 6.5(b): Cellular Proliferation of K-562 seeded onto OPLA, Collagen Composite, 









Figure 6.5(c): Cellular Proliferation of Kasumi-6 seeded onto OPLA, Collagen Composite, 


































































 Scanning Electron Micrographs of OPLA and Collagen Composite were taken at 
different time intervals. Figure 6.6 (a-f) shows OPLA scaffold seeded with HL-60 cells 48 h 
and 2 weeks after seeding. Figure 6.7 (a-d) shows Collagen Composite seeded with the same 













Figure 6.6: Scanning Electron Microscopy of OPLA seeded with HL-60 cells. a-b) OPLA at 
1 mm resolution after 48 h and 2 weeks respectively. c-d) OPLA seeded after 48 h; e-f) 


















Figure 6.7: Scanning Electron Microscopy of Collagen Composite seeded with HL-60 cells. 
a) Collagen Composite at 1mm resolution seeded after 48 h. b) Collagen Composite seeded 
after 48 hr; c-d) SEM of Collagen Composite seeded after 2 weeks in culture. 
 
6.5 DISCUSSION 
In vitro culture of native AML blasts and AML cell lines has been widely investigated in 
order to characterise these malignant cells, and because procedures involving in vitro culture 
may become useful in clinical medicine. The cell lines used in this study: K-562, HL-60 and 
Kasumi-6 have been cultured in vitro 174 by Bruserud et al. using serum-containing and 
serum free media and with a combination of cytokines. The novel aspect of this investigation 










would provide the cells with the microenvironment that they need for the secretion of their 
own ECM proteins and cytokines.  
Six scaffolds were initially evaluated by seeding them with the three AML cell lines; the 
test lasted for a period of 4 weeks. The initial tests revealed that out of the six, only PLGA 
and PU maintained cellular growth long-term consistently with the three cell lines as well as 
mechanical strength. All three AML cell lines were assessed for establishment of the culture, 
maintenance of cell growth and cellular activity. Even though the three cell lines have 
different growth kinetics (K-562 has a doubling time of 12 h; HL-60 of 48-55 h; and Kasumi-
6 of 55-72 h) and therefore results in absorbance value varied, consistent results with all the 
cell lines showed a statistically higher absorbance of PLGA and PU scaffolds over the rest of 
the scaffolds. The absorbance value is related to the number of metabolically active cells in 
the scaffold, but due to the three dimensional structure of the scaffold, creating a standard 
curve that related the number of metabolically active cells and absorbance was impossible 
(See Appendix A for standard curve graphs for 2-D and 3-D culture); as a result, the data is 
shown related to absorbance increase with time. 
After seeding the 6 scaffolds with the same cell lines the results were very different, the 
reason being due to the difference in physical and chemical properties of the 6 scaffolds. The 
hydrophobicity of the polymers could have caused the very low seeding efficiency of leess 
than 20% presented by PCL and PS which as a result, showed a decrease in cell proliferation 
over time and finally the termination of the culture before the 4 week period. On the other 
hand, in the first 24 h PLGA, PDLLA, PMMA and PU revealed comparable seeding 
efficiency results of above 60% of the cells seeded which remained in the scaffold. After the 
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4 week culture period the only scaffolds that maintained cellular growth were PLGA and PU. 
The small pore size of PMMA and the two phase structure of PDLLA could explain why the 
two polymeric scaffolds did not support cellular growth as well as PLGA and PU.  
As a result, the two selected scaffolds: PLGA and PU were taken forward as the best 
scaffolds out of the six and long-term studies were performed. The idea was to test two 
different scaffolds: one biodegradable and one non-biodegradable and evaluate them. The 
cultures lasted for 8 weeks and the results were compared with those from the commercially 
available scaffolds. Since K-562 has a known doubling time of 12 h, three times higher than 
that of either Kasumi-6 or HL-60 169, a difference in growth kinetics over the first 48 hours 
was expected when compared with the other 2 cell lines when cultivated on any polymer. 
Both scaffolds with K-562 cells showed a statistically significant higher absorbance (i.e., 
metabolic activity of cells) over all weeks of culture (p<0.01), compared with that of the 
other two cell lines; in contrast, the Kasumi-6 and HL-60 cell lines exhibited a slower 
increase in metabolic activity.  
Regardless of the AML cell line used, cells cultivated on PU displayed more metabolic 
activity than that with PLGA which can be seen in the absorbance value obtained; the 
difference is statistically significant (p < 0.05) in the case of HL-60 cell line. This difference 
between the 2 scaffolds could be explained by the difference in porosity (PLGA= 90.1% and 
PU= 85.6%) and specific pore volume (PLGA= 11.763 cm3/g and PU= 12.310cm3/g) 
between the two polymers which, in turn, affects cellular adhesion, viability, ingrowth, 
distribution, and formation of an ECM. The higher the porosity the greater the cellular 
growth response 175. PU has homogenously sized pores; in contrast, PLGA is formed by a 
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mixture of micro (≤50 µm) and macropores (≤300µm). Only PLGA macropores are capable 
of accommodating AML cells that have a varying size of 10-20µm depending on the cell line.   
The use of MTS assay to measure of cell proliferation in relation to metabolic activity has 
been a topic of controversy lately. It has been effectively proven to work in 2-D culture but 
its use in 3-D has yet to be established. The main problem arises in the accuracy of the assay 
penetration throughout the scaffold as it is the supernatant what it is used for the analysis. 
There could be gradients between the interior and the exterior of the scaffold and therefore 
the truthfulness of the assay is under question and dependent on the efficiency of metabolite 
diffusion into and out of the construct 176. In this investigation the homogeneous distribution 
and penetration of the assay was tested. The test involved the seeding of the scaffolds with 
AML cells and the subsequent analysis of the stained scaffold. A central section of: PS, 
PLGA and PMMA are shown in Appendix E. The purple stain which is the soluble formazan 
being reduced by the metabolically active cells indicates cellular activity; the stain is as 
strong as it is on the surface; hence proving the efficiency of the metabolite diffusion in the 
scaffold. 
Hydrophobicity of the scaffold material can also affect the differences in metabolically 
active cells of the synthetic polymers 177. PLGA is a hydrophobic polymer and therefore 
possesses high interfacial free energy in aqueous solutions that tends to unfavourably 
influence cells and tissues during the initial stages of contact 178. The cells adhere and grow 
better on hydrophilic scaffolds, such as PU, than on hydrophobic surfaces 179,180; These 
differences in hydrophobicity may explain the higher number of metabolically active cells in 




 The testing of the six polymeric scaffolds for AML cell growth concluded with the 
selection of the two of them as the most suitable and long-term studies were performed on 
them. Nevertheless, even if the selected synthetic polymers displayed good results and can 
offer several advantages for engineering applications, such as low density, good electrical 
and thermal insulation, flexibility, low weight, ease to manufacture and cost-effectiveness to 
name a few, they have the drawback of the problems with cell affinity, hydrophobicity and 
the lack of cell recognition signals of the materials. The hybridisation of the synthetic 
polymeric scaffolds with ECM proteins offers a solution to some of the problems because it 
can increase the cell interaction and hydrophilicity of the material, while maintaining the 
mechanical strength.  Adding an ECM coating to the synthetic polymer scaffolds would 
provide an “adhesive” interface between the scaffold and the cells. The coating provides a 
binding sequence for the cells and also provides a site for secondary interactions between 
other ECM proteins and growth factors which can enhance cell growth. Hence, despite the 
promising results obtained when using PLGA and PU as 3-D scaffolds to culture AML cells, 
the scaffolds lack cell-recognition signals and are very hydrophobic. In contrast, naturally 
derived collagen and fibronectin have the potential of specific cell interactions and 
hydrophilicity but poor mechanical strength. Therefore the combination of a synthetic 
scaffold and a natural derived polymer could help optimise the obtained data 160. This topic 












7.1  INTRODUCTION 
Interactions between scaffolds are dictated by the cell’s response to the polymeric 
material; in many cases the lack of cell recognition signals on the scaffold surfaces and their 
hydrophobicity result in the inability of the scaffold to support cellular growth. The 
biosignals of the niche in the BM control cellular behaviour and therefore, ECM-based 
polymers offer a solution and a high affinity for cell interaction but on the other hand, lack 
the control over desired degradation and mechanical properties of the 3-D synthetic scaffolds 
181. For this reason, in order to mimic the BM in both its 3-D structure and its provision of 
appropriate biosignals for cell attachment, the modification of the synthetic polymer with 
ECM proteins offers an ideal solution to overcome the limitations of the scaffolds. Currently 
ECM-derived molecules are used to coat implants, modify surfaces or direct cell growth and 
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differentiation 182; and have been hybridised to combine the advantageous properties of both 
constituents 160. Collagen-PLLA hybrid scaffolds 183 or PLGA-Collagen 184 have been tested 
with success by introducing collagen microsponges into the pores of the synthetic scaffolds. 
The coating of the scaffolds with ECM proteins would provide an adhesive interface, 
together with a strong mechanical contact between the scaffold material and the cells; whose 
organisation and production modulates and enhances cell adhesion through transmembrane 
integrin receptors. The advantage to incorporate the ECM proteins to the synthetic scaffolds 
is that not only they would provide the cell-binding sequence for cell adhesion, but also 
provide secondary interactions with other ECM proteins and interactions with growth factors 
that stabilise the binding of the cells thus enhancing cell adhesion, which results in better cell 
growth and maturation 185.  
 
For this reason the combination of a highly porous scaffold that defined the limits of the 
bone marrow and provided mechanical stability, and ECM proteins was studied. It 
represented a structure that does not exist now for three dimensional AML culture and 
investigation. Based on these criteria, PLGA (biodegradable) and PU (non-biodegradable) 
were selected from the studies presented in Chapter 6 and coated with two ECM proteins 
37,47: fibronectin and collagen type I; the first one in order to provide an adhesive interface 





7.1.1 Surface Modification 
There are several physicochemical  methods that can be used for surface modification 
which include:  surface coating, chemical modification, and plasma treatment to name a few 
187. ECM-coating of scaffolds is an interesting option and an important parameter to consider 
in tissue engineering of 3-D cellular cultures 188-190. In this investigation, several coating 
methods were tested before seeding them with cells 184,191 until homogeneous coating of the 
scaffold was obtained; our method allowed the penetration throughout. This section is limited 
to describe the ECM components and in particular the two proteins used in the investigation: 
the structural protein collagen type I and the specialised protein, plasma fibronectin. 
Collagen Type I 
Collagen is the main protein component of connective tissues and basement membrane 
and makes up one-third of all the protein in the body 192. There are several different types of 
collagen, being the most abundant types I, II and III. Collagen type I is found in high 
concentrations in tendon, skin, bone and fascia; it is essential for the tensile strength of bone; 
it is the final amount and distribution of these collagen fibers that will determine the size, 
shape, and ultimate density of the bone 193. Collagen is part of the basement membrane 
surrounding the blood vessel endothelium, together with proteins and proteoglycans, such as 
laminin, entactin, fibronectin, heparin, sulfate and perlecan; this membrane acts as a physical 
barrier between the epithelium and underlying tissues. It provides cell surface anchorage (via 
integrins, receptor kinases, and cell surface proteoglycans), induces cellular differentiation, 
gives architectural support, and limits the migration of normal cells. The ability of tumor 
cells to degrade the ECM components of the basement membrane and surrounding tissues is 
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directly correlated with metastatic potential. By releasing proteolytic enzymes cancer cells 
are able to breach the membrane and penetrate the blood vessel wall. Collagen, the primary 
structural element of the basement membrane and tissue scaffolding protein, represents the 
main deterrent in the migration of tumor cells. Collagen scaffolds have been investigated as 
polymeric devices to support cellular growth on their own. Although there are 19 different 
types of collagen, type I and II are the most commonly used in tissue engineering due to the 
fact that type I is the most abundant type and can be mineralised and type II is predominant in 
hyaline cartilage 140. Collagen is a very tough protein and is normally cross-linked using 
various techniques to improve its physical properties. The techniques include: glutaraldehide, 
carbodiimide or photooxidation 194 . 
Fibronectin 
Fibronectin is an important high molecular weight glycoprotein that binds integrins as 
well as components of the ECM including collagen, fibrin, and heparin. Fibronectin can be 
found in the blood plasma in its soluble form, which is composed of two 250 kDa subunits 
joined together by disulfide bonds 195,196 and in insoluble form in loose connective tissue and 
basement membranes. The insoluble form that was formerly called cold-insoluble globulin is 
a large complex of cross-linked subunits. Fibronectin binds to cell surfaces as well as to other 
ECM proteins and is involved in various processes such as wound healing, cell migration, 
cell proliferation, coagulation and maintenance of cell cytoskeleton 192. It is also one of the 
few proteins for which production increases with age without any associated pathology. In 




7.2 AIM AND HYPOTHESIS 
It was hypothised that the combination of a highly porous scaffold that resembled the 3-D 
architecture of the BM and ECM proteins of the BM, would provide the necessary cues and 
biosignals for the AML cells to establish themselves ex vivo in culture and expand.  
 
7.3 APPRAOCH TO STUDY 
Coating of PU and PLGA synthetic scaffolds with ECM proteins was thought to improve 
and maintain AML cell lines in vitro. In order to mimic the bone marrow microenvironment 
and enhance the cell culture, PU and PLGA scaffolds were coated with two of the main bone 
marrow ECM proteins, collagen type I and fibronectin, and  evaluated at either high (125 
µg/ml for collagen type I and 50 µg/ml for fibronectin) or low concentrations (62.5 µg/ml for 
collagen type I and 25 µg/ml for fibronectin) or using a combination of collagen and 
fibronectin using the low concentrations (62.5 µg/ml of collagen and 25 µg/ml of 
fibronectin). The concentrations used were taken from previous studies 197,198.  
7.4 RESULTS 
7.4.1 Seeding Efficiencies 
 The seeding efficiency shows the percentage of cells that remain in the scaffold after 24 h 
of seeding. The effect of protein coating the scaffolds was studied and compared with that of 


















Figure 7.1 Seeding Efficiency of coated and uncoated PLGA and PU.  Collagen coated with 
125 µg/ml seeding efficiency was statistically higher (p<0.05) than the scaffolds coated with 
fibronectin at the two concentrations. N = 3. 
 
For all cell lines, seeding efficiency was consistently over 50% in the scaffolds coated 
with collagen type I at the high concentration (125 µg/ml) and is statistically significant 
(p<0.05) the difference between this one and the scaffolds coated with fibronectin when 
using any of the two concentrations (50 and 25 µg/ml). In contrast, the untreated scaffolds 
















































scaffolds with fibronectin alone was of no proven benefit to the AML cultures in these 
studies, PLGA scaffolds coated with fibronectin and collagen at the low concentration (25 
µg/ml and 62.5 µg/ml respectively) displayed a higher result but not statistically significant. 
Overall, PU coated with collagen type I (125 µg/ml) was best for seeding efficiency of all 3 
cell lines. 
7.4.2 Cell Proliferation 
Cellular proliferation of the 3 AML cell lines cultivated on ECM-coated PU and PLGA 
was measured using the MTS assay over a period of 6 weeks. Although quite different 
growth patterns were evident at each time point, a common finding in all cultures was that 
cell growth on the ECM-coated scaffold was at least as good as, and at most time points 
better, than that on the control uncoated scaffold. In the cell-line specific analysis, HL-60 
growth showed in figure 7.2 (figure 7.2(a) when seeded onto PU and figure 7.2(b) when 
seeded onto PLGA) was enhanced at the early stages of the culture when supported by PU 
coated with fibronectin (50 µg/ml) although by week 5, the culture was best supported by 
collagen type I (62.5 µg/ml). In contrast, the same cell line displayed different behaviour 
when seeded in PLGA, with enhanced growth in the collagen coated (62.5 µg/ml) scaffold 
early (by week 2), and later improvement in proliferation with scaffolds coated in fibronectin. 
Overall, an enhanced HL-60 growth is observed when coating the scaffolds with ECM 
proteins (p<0.05); with an initial higher proliferation onto the PLGA fibronectin coated 
scaffolds which changed to the collagen coated scaffolds in the last stages of the culture. 
Thus, a consistent and stable pattern of growth is observed with the support of scaffolds 

















Figure 7.2 (a): HL-60 cellular proliferation onto coated PU.  The MTS assay gives a measure 
of cellular proliferation in relation to the absorbance. The two lines: dotted and straight, show 
the growth trends of collagen coated (62.5 µg/ml) (dotted) and the control (straight) over the 




































































































Figure 7.2 (b): HL-60 cellular proliferation onto coated PLGA.  Similar behaviour was 
detected when seeding the cells onto PLGA as the dotted line (growth trend of collagen 
coated 62.5 µg/ml) and the straight line (control) have a comparable speed. Although it has to 
be noted that the absorbance is lower when using PLGA than when using PU. N = 3. 
 
 Growth trend lines were added to the collagen coated scaffolds with 62.5 µg/ml and to 
the untreated scaffolds to show that coating results in a two step process; when the cells were 
seeded they needed to adapt to the new environment and remained without differentiation for 
a few days to adapt and start expanding until they reach a peak proliferation point. For the 
collagen coated scaffolds this period took 3 weeks and when seeded onto the uncoated 
scaffold it took 4 weeks. For the control scaffolds, that is for the uncoated scaffolds, this 
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culture adaptation and proliferation period took 4 weeks again for both scaffolds. After the 
cells adapted to their new environment, the proliferation stabilised; in the case of the collagen 
coated scaffold the cultures stabilised at week 4 and in the uncoated scaffolds the culture did 
not stabilised until week 5. 
K-562 cells grew faster than the other 2 cell lines on the scaffolds treated with ECM 
proteins (Figure 7.3: (a) PU and (b) PLGA), and is indicated by the higher absorbance 
readings obtained and due to the fact that they have a doubling time of 12 h, which is almost 
three times higher than the other two cell lines. When cultures on PU, cellular growth was 
high and similar amongst all conditions until 4 weeks when the cell proliferation was best on 
the collagen treated (62.5 µg/ml) scaffolds until 6 weeks when the cultures were stopped.  In 
contrast to the behaviour observed with HL-60, K-562 displayed rapid growth when 
supported by PLGA with fibronectin (50 µg/ml; figure 7.3b) in the early stages of the culture, 


























































Figure 7.3 (a): K-562 cellular proliferation onto coated PU. The growth trends of the 
collagen coated (62.5 µg/ml) and the control scaffolds are show in the graph. The dotted line 
shows the collagen coated scaffold and the straight line shows the control scaffold 






















































Figure 7.3 (b): K-562 cellular proliferation onto coated PLGA.  The absorbance in this case 
is lower than when using PU, although the growth trends are comparable. The dotted line 
shows proliferation and culture stabilisation of the scaffold coated with 62.5 µg/ml of 
collagen and the straight line shows the uncoated PLGA comparison. N = 3. 
 
Collagen coated at 62.5 µg/ml and uncoated scaffolds were selected at the end of the 
investigation as the most suitable scaffolds for AML cell culture; that is the reason why they 
are represented here. When using K-562 the period where the cellular culture adapted and 
proliferated took 4 weeks for both scaffolds: coated and uncoated. Culture stabilisation was 
reached at week 5 of the investigation.   
The Kasumi-6 cell line (Figure 7.4) grew best when seeded on PU coated with 62.5 










































0.05). Growth of the cell line in the other conditions tested was not statistically different 
when compared with that of the untreated PU scaffold. On PLGA (Figure 7.4b), Kasumi-6 
cells showed a higher absorbance value on ECM-coated scaffolds than on the uncoated 








Figure 7.4 (a): Kasumi-6 cellular proliferation onto coated PU. The graph shows cellular 
proliferation of Kasumi-6 seeded onto PU over a period of 6 weeks. Absorbance when using 
this cell line is lower as a result of the slow growth of the cell line. The doubling time of 
Kasumi-6 is of 55-72 h and culture medium needed the addition of growth factors. N = 3. 
 
 Cellular proliferation was measured when using Kasumi-6 cell line. The absorbance is 












































is very delicate and requires addition of growth factors (GM-CSF) to proliferate. When using 
this cell line the two step culture (proliferation and stabilisation) observed in the other two 
lines did not exist; in this case the culture development was slower and at 6 weeks only the 








Figure 7.4 (b): Kasumi-6 cellular proliferation onto coated PLGA. The cellular proliferation 
when using Kasumi-6 onto PLGA is slower than when using the other two cell lines. The 
dotted and straight lines represent the growth trends of collagen coated (62.5 µg/ml) and 
uncoated respectively. In this case and after 6 weeks only the adaptation and proliferation 
step can be seen. Culture stabilisation it was assumed to occur after a period longer than 6 




 After week 3 in culture, growth was similar in all the scaffolds tested as there was not 
statistically difference between any of them. Only in week 2 and in week 3 the protein coated 
scaffolds were statistically significantly higher than the control (p<0.05) which in this case is 
the uncoated PLGA. 
 
7.4.3 Assessing Cell Attachment and Spreading using SEM  
AML cells formed cell aggregates in scaffold niches. Characterisation of the 3-D 
scaffolds and cell morphology was carried out using scanning electron microscopy at 48 
hours, 2 and 4 weeks after seeding. Figure 7.5 shows SEM micrographs of PU and figure 7.6 
of PLGA. Over a period of 4 weeks, the cells migrated into the pores of the scaffold 
establishing and defining areas of growth, or “niches”. When SEMs of AML-cell-seeded 
PLGA and PU scaffolds were compared, the cells observed were adhering better in the PU 
scaffolds. Cellular density in the pores increased with time and by week 4 the walls of the 










Figure 7.5: SEM of PU coated with ECM proteins: (1) 48 h after seeding Kasumi-6 on 62.5 























Figure 7.5: SEM of PU coated with ECM proteins: (3) 2 weeks after seeding HL-60 on 125 





















Figure 7.5: SEM of PU coated with ECM proteins: (5) 4 weeks after seeding HL-60 on 125 












 Figure 7.6 shows the SEM micrographs taken of PLGA coated and seeded with the three 









Figure 7.6: SEM of PLGA coated: (1) 48 h after seeding Kasumi-6 on 125 µg/ml Collagen 





















Figure 7.6: SEM of PLGA coated: (3) 2 weeks after seeding HL-60 on 62.5 µg/ml Collagen 




















Figure 7.6: SEM of PLGA coated: (5) 4 weeks after seeding Kasumi-6 on 125 µg/ml 













   
7.5 DISCUSSION 
The interaction of the cells with the material where they are seeded is a result of specific 
cell surface adhesion receptors, integrins and ECM proteins that have a cell-binding domain. 
Controversely, the synthetic polymeric scaffolds tested in Chapter 6 lack the natural 
recognition sites of the cells to the material and are very hydrophobic, making it difficult for 
the cells to interact with the material. Even though the mechanical properties and 
biocompatibility criteria needed for bone tissue engineering have been met previously by the 
synthetic polymeric scaffolds selected: PLGA and PU 199, that was not enough. To try to 
overcome the hydrophobicity problem pre-wetting the scaffold with ethanol was used.  
Several coating methods have been reportedly used to improve the surface properties of 
PU and PLGA to enhance cell compatibility, and included the proteins used in this 
investigation: fibronectin and collagen. Fibronectin 200, increased surface smoothness and 
hydrophilicity properties of the PU and collagen 201 supported tissue integration. In the case 
of PLGA, when coated with collagen to culture fibroblasts 202 it aided the secretion of ECM 
proteins. PLGA coated with collagen and fibronectin has also been used to induce cell 
migration 203 in polymer films. 
 In addition, as scaffolds designed to mimic the bone marrow should resemble the in vivo 
structure, morphology and function in order to optimise cellular proliferation ex vivo, it was 
thought to mimic its composition as well. Bone marrow is formed by three different 
constituents: living cells; non-living organic such as collagen; and non-living inorganic 
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crystals (hydroxycarbonate apatite, HCA); the crystal structure is deposited within an organic 
matrix formed mainly (95%) of collagen type I 204. Since ECM-coating of scaffolds is an 
important parameter to consider in the tissue engineering of 3-D cellular cultures 188-190 it was 
decided to investigate this further and to coat the scaffolds with two very common ECM 
proteins: collagen type I and fibronectin. Given that cellular growth can be affected by the 
method used to coat scaffolds with proteins, it was very important to achieve homogeneous 
coating and suitably results.  Most methods have been based on immersion of polymer films 
and matrices 189 which may result in non-uniform distribution and poor penetration of the 
protein into the scaffold. In this investigation several coating methods were tested 184,191; 
ultimately, a centrifugal method for coating was selected resulting in good penetration and 
homogeneous coating of the scaffold even in the central sections evaluated by 
immunohistochemistry.  
The use of peptides instead of proteins as coating material to optimise scaffolds was 
additionally considered in this investigation. Peptide coating has numerous advantages due to 
the fact that peptide orientation and surface density can be controlled and, by incorporating 
peptides to the materials, it could reduce its biodegradation. However, the use of complete 
ECM proteins was considered to be better for porous 3-D scaffolds because not only they 
could provide the cell-binding sequence for cell adhesion, but also provide secondary 
interactions with other ECM proteins and growth factors. Small peptides have lower binding 




As a result, 3-D systems were developed: scaffolds made of 2 different synthetic 
polymers: PLGA and PU, to culture AML cell lines and the possible coating with different 
concentrations of collagen type I and fibronectin to improve cellular proliferation was tested. 
Overall, the collagen-coated scaffolds displayed a cell seeding efficiency of greater than 
50%. Conversely, fibronectin-coating alone of polymer scaffolds did not improve cell 
adhesion or promote cell ingression (as determined by seeding efficiency) but fibronectin 
combined with collagen at low concentration (25 µg/ml + 62.5 µg/ml) promoted a cell 
seeding efficiency higher than that of the uncoated scaffolds. Collagen accelerated cell 
adhesion when compared with other ECM proteins 190 and may explain the observed 
superiority of the collagen-coated scaffolds at cell seeding efficiency within 24 hours. In 
general, when comparing the seeding efficiency of the coated and the control scaffolds, it 
shows that there is no statistical difference between the two groups; but after completing the 
study, the coated scaffolds showed enhanced results. This low seeding efficiency could be 
due to the blockage of the pores by the protein coating. Even though the coated scaffolds 
were centrifuged in PBS to remove any obstruction of the surface pores, there is a possibility 
that there was a change in pore size and porosity and the cells did not penetrate as easily as 
they did when seeded onto the control scaffolds.   
 Interestingly, 2-D culture of hematopoietic progenitor cells with fibronectin enhances 
preservation of the normal progenitors but not abnormal chronic myelogenous leukemia 
(CML) cells in the same culture 206. Similarly, in this study, it was shown that after 6 weeks 
cultivation of AML cell lines, prolonged cultures were more metabolically active with 
collagen-coated scaffolds rather than with scaffolds coated with fibronectin. Collagen 
stabilised cell growth even after 4 weeks of culture and facilitated cell expansion – a similar 
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behaviour has been observed for hepatocyte cultures on PLLA coated with collagen, with 
growth stabilised after 2 weeks in culture 189. Other researches have used a  bone marrow 
model as a three dimensional scaffold for the study of erythropoesis and the growth kinetics 
are comparable to this model 55. 
It was observed that PU coated with 62.5 µg/ml of collagen type I, although did not show 
the highest absorbance values in all the experiments, overall it had a homogeneous result that 
was validated with the three cell lines. It sustained the best growth of leukemic cells 
compared with that of fibronectin and a higher concentration of collagen (125 µg/ml), and 
conclude that, in our hands, the combination of PU-collagen 62.5 µg/ml is best for the 3-D 
cultivation of the AML cell lines studied in this work. Interestingly, protein coated PLGA did 
not display any statistically significant improvement in cell growth using any of the cells 
lines; although there was the exception of K-562 cell line that when seeded in 25 µg/ml 
fibronectin coated PLGA and the combination (25 µg/ml of fibronectin and 62.5 µg/ml of 
collagen) which showed a statistically significant improvement in cellular growth, hence 
using PLGA as an uncoated scaffold using a wide range of cell lines resulted in better cell 
seeding efficiency and proliferation than that which was the protein-treated. Different results 
were obtained for different cell lines. In the case of HL-60 and Kasumi-6, the cellular growth 
after 4 weeks was higher in the uncoated scaffolds than in any of the other coated ones, 
although the absorbance in Kasumi-6 was lower due to the slow growth kinetics of the cell 
line and the necessity to add growth factors for its expansion.  However, the cells seeded onto 
the scaffolds followed the same growth trend in both cases, coated and uncoated but differed 
in the phase when the culture became steady. For uncoated scaffolds, culture stabilisation 
 139 
 
occurred after week 4 and in the case of coated samples, the stabilisation was accelerated and 
the cultures became steady by week 1-2 depending on the cell line. For this reason, coating 
the scaffold with collagen and fibronectin accelerated the growth kinetics of the cells, 
perhaps through enhanced adherence of the cells to the scaffold.  
7.6 CONCLUSION 
This chapter has described how the three dimensional, highly porous environment of the 
PU scaffold coupled with collagen type I coating was optimal for sustaining and stabilising 
the growth of three different AML cell lines over a period of 6 weeks. The combination of a 
highly porous scaffold, similar to that defined by the bone marrow architecture, with bone 
marrow-specific ECM proteins (collagen type I and fibronectin) it was thought to provide a 
3-D structure for sustainable in vitro cultivation and study of primary AML cells in a 
biomimetic environment ex vivo. Both cell-matrix and cell-cell interactions may be 
investigated further in this novel experimental system in order to investigate the pathogenesis 
of the disease and to explore novel treatments for leukemia. In average, the results showed 
that PU coated with collagen (62.5 µg/ml) at several time intervals was statistically higher 
and outperforms the other scaffolds for growth of AML cell lines in vitro in 3-D culture 














8.1  INTRODUCTION 
Human umbilical cord blood (CB) is rich in long-term repopulating hematopoietic stem 
cells (LTC-IC) 207. CB is collected after the umbilical cord has been detached from the 
newborn, and utilised as a source of stem cells for transplantation. In the last decade there 
have been more than 8,000 related and unrelated CB transplants 208 and play an important 
role in improving the donor HSC pool for minority populations currently poorly represented 
in donor registries 209. Other advantages include the ease of collection and spread availability, 
the low severity of graft versus-host disease (GVHD) and the less stringent requirement for 
HLA blood group matching between donors and recipients 210. The number of primitive cells 
that have higher self renewal capacity in CB is higher than in the bone marrow (BM) and 
peripheral blood (PB) and also it contains enough number of stromal cells that support 
hematopoiesis 211-215. Cell cycle kinetic analysis of the cells when taken immediately from the 
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CB upon birth have demonstrated the very slow, non-dividing state of the cells in contrast to 
the relatively high proliferation rate of these cells in the marrow 216. However, the cells in the 
CB when in contact with growth factors while being ex vivo expanded responded very 
quickly 217. Conversely, the content of progenitors in the cord is very low and limited by the 
cord harvested, compared to BM or PB which can result in a slowest engraftment of the CB 
when transplanted. Since the degree of engraftment is dependent on the number of 
transplanted cells and the CD34+ content in CB is 0.5-1% of nucleated cells 215, this has 
resulted in the use of CB transplants mostly in patients with low body weight hence children. 
There has been some success in engraftment of adults and higher weight children but the 
numbers of cells collected from single cord blood collections have been considered dose-
limiting for most adults. The minimal dose for a CB transplant proposed by Gluckman et al is 
> 3 x107 nucleated cells (NCs) per kg of body weight 218. As a result, increasing ex vivo the 
number of progenitor cells in CB has become a promising approach to improve the 
applicability and the outcome of the transplant. 
Numerous studies have been done on ex vivo CB expansion using 2-D and 3-D culture, 
although the expansion of primitive stem cells such as Lin-/CD34+ is still a matter of debate. 
The 2-D culture includes the use of automated perfusion systems 219, the liquid suspension 
culture of CD34+ cells for long periods of time 220 and the expansion using dextran 
sedimentation and avidin column selection 221. All these methods include the addition of 
exogenous cytokines to maintain the expansion of the CB cells. The cytokines normally used 
for this purpose are: Stem Cell Factor (SCF), Flt-3 ligand (FL), Thrombopoietin (TPO), 
granulocyte colony-stimulating factor (G-CSF), IL-1, IL-3, IL-6 and others 222-227. FL and 
TPO are believed to support self-renewal of primitive stem cells by preventing the telomere 
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degradation that occurs with proliferation 27; SCF and IL-6 possibly enhance the proliferative 
potential of subpopulations of HSCs 228. The addition of large amounts of these growth 
factors for the expansion of the cells ex vivo is very expensive (more than $10,000) and does 
not correspond in concentration to the amount found in nature; the cytokines are added ex 
vivo in the range of ng/ml whereas in the BM the concentration is much lower (pg/ml). 
Other examples of CB expansion included the coculture of CB MNCs with MSCs and are 
thought to better preserve the component of the more primitive, long term repopulating cells, 
while also producing lineage-committed cells. The advantage of this method is that no 
isolation of the CB HSCs is needed therefore reducing the loss of HSCs during manipulation. 
The method involves the use of FBS and a cocktail of growth factors as with liquid culture 
expansion 229. A 10-20 fold increase in TNC, 7-18 increase in committed progenitor cells, 
and a 17-37 fold increase in CD34+ cells has been reported when using this method. 
A small number of 3-D culture systems are known to be able to expand HSCs ex vivo but 
the majority use BM MNCs, which are different from CB in terms of HSCs and non 
hematopoietic cells 230. Due to the fact that ex vivo expansion of CB applies the same 
expansion strategies than BM and PB derived HSCs it is also know that CB ex vivo 
expansion posses an inherent reduction in long-term hematopoietic reconstruction potential in 
favour of the short-term reconstituting potential over a long period. Some examples of the 3-
D culture systems include the nonwoven polyethylene terephthalate (PET) matrix 231 which 
expands CB in 3-D and supports higher total cell number and colony forming units (CFU) 
production;  other systems such as the tantalum-coated porous biomaterial (CellFoam) 65 or 
the porous collagen microspheres and collagen coated nylon mesh were used to culture 
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murine BM cells and rat BM cells respectively and were found to maintain multilineage 
differentiation  but low and decreasing numbers of CFU 55,85. Exogenous cytokines were also 
added in these experiments. Another question that was investigated was the use of a serum 
free or serum containing media; the latest trend has been so far to use a serum free media 232. 
The use of bioreactors has also been explored; AstromReplicell is one example, together with 
a growth factor cocktail consisting of: PIXY321, Flt-3 ligand and EPO although the outcome 
remains uncertain; the phase I trial test showed no difference with patients not receiving the 
transplant from expanded CB cells 215.  
8.2 AIM AND HYPOTHESIS 
As the BM microenvironment in vivo is distributed in a 3-D space and plays a critical role 
in hematopoiesis 231,233, maintaining stem cell potential and controlling proliferation and 
differentiation, it has some factors that in absence or presence may result in one outcome or 
another. The identification of these factors although still unclear it could help elucidate these 
questions. As a result, it was hypothesised that by recreating the 3-D porous structure of the 
BM, CB MNCs would, when seeded onto the scaffolds, secrete their own ECM proteins, and 
the hematopoietic and the non-hematopoietic stem cells would start proliferating in the 
artificial scaffolds without the need of adding exogenous cytokines and truly recreating the 
natural in vivo environment. For this chapter a 3-D culture system that could expand CB 





8.3 APPROACH TO STUDY 
Two different polymers were studied as scaffolds for CB expansion. In the previous 
chapters it was suggested that out of all the synthetic polymeric scaffolds tested, the optimal 
ones for this investigation were poly (L-lactic-co-glycolic acid) (PLGA) and polyurethane 
(PU). As mentioned before, both are biocompatible, biodegradable and non biodegradable 
respectively, FDA approved and are extensively used in biomedical engineering applications 
125-129. These polymeric scaffolds can be fabricated to ensure adequate pore size and a high 
surface area to volume ratio, key parameters of the internal surface, in order to enable the 
formation of a complex network of channels and interconnected pores for enhanced 
penetration of large numbers of cells and the formation of cellular associations 234,235. 
However, the lack of cell recognition signals, low surface energy or hydrophobicity of many 
synthetic polymers hinders smooth cell seeding. In contrast, extracellular matrix (ECM) 
proteins offer specific cell interaction and hydrophilicity but, on their own, are unable to 
provide the mechanical strength required of a scaffold. Hence, following the results presented 
in Chapter 7, PU was coated with an ECM protein, collagen type I, to provide a stronger 
mechanical contact between the scaffold material and CB cells 186; PLGA however, remained 
as its best when uncoated.  In this chapter the results obtained when tested the two polymeric 
scaffolds for their potential use in CB MNC expansion were tested, and the results are here 
presented.  
8.4 RESULTS 
Two polymeric scaffolds: PLGA and PU were tested and seeded with CB MNCs. 
Previous studies on PU scaffolds seeded with AML cells suggested that protein coating of the 
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polymer could improve its performance. The same technique applied before was used here 
but used CB MNCs instead. PU was coated with an ECM protein secreted by the cells in 
vivo: Collagen type I, using a concentrations of 62.5 µg/ml 198 normally employed to add 
mechanical strength in tissue engineering. The effect of protein coating of PU was 
investigated and compared with the uncoated scaffolds. Table 8.1 summarises the physical 
properties of the two polymers prior seeding. 
Table 8.1: Physical properties of PLGA and PU.  The table summarises the principal 




Poly (lactide co-glycolide) Polyurethane 
Scaffold diameter                (mm) 5 5 
Density ρ                          (g/cm3) 1.5±0.03 1.2±0.02 
Specific pore volume Vp    (cm
3/g) 11.8±1.3 12.3±1.4 
Surface area As                  (m
2/g) 0.6 1.0 
Porosity                                  (%) 94.7±1.3 93.9±0.04 
Pore size range                     (µm) 
micropores 50-100 µm and 




8.4.1 Seeding Efficiency 
 Seeding efficiency is a measure of the cells that remain in the scaffold after 24 h of 
culture and tested to be higher in the samples seeded onto PU scaffolds and especially in the 
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ones coated with collagen type I (Figure 8.1). The seeding efficiency was above 70% for all 










Figure 8.1. Seeding Efficiency of the three selected scaffolds using CB MNCs.  Seeding 
efficiency of the scaffolds cultured with CB MNCs was tested after 24 h of culture; the 
results showed a higher seeding efficiency compared to AML cell lines. Overall the seeding 
efficiency was above 70% in all the cases. N = 3. 
 
Seeding efficiency of the scaffolds when seeded with CB MNCs was proven to be higher 
than when seeded with AML cell lines. Overall, the efficiency was greater in all the scaffolds 
showing the affinity of the MNCs to the materials evaluated, which aided cellular expansion 
and proliferation. MNCs are formed by a group of cells from the hematopoietic system that 
have a characteristic in common, they do not contain granules; these cells include: 






























lymphocytes, plasma cells, monocytes and macrophages. There was no statistically 
significant difference between seeding efficiency of the 3 scaffolds tested. 
 
8.4.2 Cell Proliferation and Viability 
Cellular proliferation in the scaffolds was evaluated over a period of 28 d using the MTS 
assay, which gives a measure of the absorbance in relation to the number of metabolically 
active cells. Continuous cellular expansion of the MNCs in the three scaffolds tested is 
shown in figure 8.2. At the early stages of the culture PLGA seemed to enhance the culture 
but as the culture progressed there was an increase in cell expansion when using PU which 
was empowered by the collagen coating. The peak value was reached at day 28 where 
cellular activity was significantly different in the sample of PU coated with collagen when 
compared with PLGA (p<0.05); only at this point the difference in proliferation was statically 
different from the other scaffolds. Viability of the cells was measured over the same period 
and is shown in Figure 8.3; at day 0 prior cell seeding and at days 2, 14 and 28. PLGA 
exhibited a viability of 75% which was lower that in the case of the cells seeded in PU where 











































Figure 8.2. MTS of the CB MNCs over a period of 28 d. The columns show the growth 
trends of the cells when seeded in the three different scaffolds; in all the cases there is a 



























Figure 8.3. Viabilities of the CB MNCs seeded onto PLGA and PU scaffolds during a period 
of 28 d. The cells were more than 90% viable when seeded onto PU scaffolds but the 
viability decreased to under 75% when seeded onto PLGA scaffolds. N = 2. 
 
8.4.3 DNA Quantification 
DNA was quantified using PicoGreen® fluorescent dye which undergoes a dramatic 
fluorescence enhancement upon binding to double stranded DNA that can be measured using 
a microplate fluorometer. Figure 8.4 shows the DNA Quantification results in relation to the 
number of cells (standard curve for DNA Quantification is included in Appendix C). From 
the data it can be seen an expansion of the cells in the three scaffolds tested. PLGA expansion 
is very moderate in comparison with the expansion achieved by the cells seeded onto the PU 
coated scaffold, where the expansion after 28 d in culture was of 53-fold, PU has an 
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expansion of 20-fold and PLGA of 7-fold. This is in concordance with the data obtained by 
the MTS assay which showed a similar increase in cellular expansion and also proved the 
superiority of the PU coated scaffold which is statistical significant (p<0.05) when compared 
with the other two scaffolds. The statistically higher number of cells in the PU coated 
















Figure 8.4: DNA Quantification of PLGA, PU and PU coated with 62.5µg/ml of collagen 
type I seeded with CB MNCs at day 0, 14 and 28.  The graph shows the statistically 
difference in number of expanded cells when seeding MNCs onto PU collagen type I coated 





























8.4.4 Colony Forming Units 
The colony forming unit (CFU) assay is a cytogenic technique used for measuring the 
functional capacity of stem cells by assaying their activity. This assay was performed on the 
scaffolds at day 0, before the cells were seeded onto the scaffolds and the data was used as 
the control, at day 14, and at day 28 (Figure 8.5). The results showed that after 28 d in culture 
there were still progenitor cells in the form of Colony-Forming Units-Granulocyte, 
Erythrocyte, Macrophage, Megakaryocyte (CFU-GEMM) in the three scaffolds tested, 
suggesting that the MNCs were producing their own growth factors in the 3-D scaffolds. 
There was a uniform number of Colony-Forming Unit-Granulocyte, Macrophage (CFU-GM) 
that was maintained from day 14 to day 28 but there was an increase in the number of Burst-
Forming Unit Erythroid (BFU-E) which was more intense in the case of the MNCs seeded on 
PU uncoated. More differentiated cells were determined by the number of Colony-Forming 
Unit-Erythroid (CFU-E) and it can be appreciated from the results that the number decreased 
with time, indicating that the cells were in a more immature state than the CFU-E. Overall, 
the results showed a similar behaviour of the colonies in the three scaffolds tested, where the 
MNCs after 28 d in culture adopted a differentiation pattern towards the erythroid lineage but 
did not differentiated totally yet. 
When using PLGA, the increase in numbers of BFU-E and GM-CFU was statistically 
significant than the control (p<0.05); in the case of PU in the two forms: coated and 
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Figure 8.5: CFUs of CB MNCs seeded on PLGA and PU. Samples were analysed at day 0, 
14 and 28 and the number of colonies were counted in the three scaffolds studied. N = 2. 
 
 Scoring CFUs by short-term culturing in semi-solid media provided information 
regarding the lineage committed and proliferative potential of the cells, but quantifying the 
colonies was uncertain and depended on the protocol used in the laboratory. Figures 8.6, 8.7, 
and 8.8 illustrate the colonies taken as reference for scoring during the 3 time intervals tested: 












Figure 8.6: CFU microscope pictures taken at day 0 prior cell seeding. a) BFU-E, b) CFU-E, 









































Figure 8.8: CFU microscope pictures taken at day 28. a) BFU-E, b) CFU-E, c) CFU-GEMM, 
d) CFU-GM. 
 
8.4.5 Cell Morphology and Scaffold Characterisation 
Characterisation of the 3-D scaffolds and cell morphology was done using SEM for cell 
distribution and surface topography after 0 d, 14 d and 28 d of cell culture in the scaffold. 
The SEM micrographs (Figures 8.9-8.17) demonstrate how over a period of 28 d, the cells 
migrated into the pores establishing themselves in “niches”. When comparing the SEM of 
cell seeded PLGA and PU scaffolds, it appears that the cells adhere better when seeded onto 
PU scaffolds. Cellular density in the pores increased with time, and by week 4 the walls of 














Figure 8.9: Scanning electron micrograph of PLGA seeded with MNCs at day 0. The picture 
was taken of a central section of the scaffold. Different types of cells such erythrocytes, 




















Figure 8.10: Scanning electron micrograph of PLGA seeded with MNCs at day 14. Cellular 











Figure 8.11: Scanning electron micrograph of PLGA seeded with MNCs at day 28. The 












Figure 8.12: Scanning electron micrograph of PU seeded with MNCs at day 0. This axial cut 
central section of the scaffold shows the cells concentrated into the pores after they have been 











Figure 8.13: Scanning electron micrograph of PU seeded with MNCs at 14 days.  The cells 
migrated into the pores and established into “niches”. The walls of the pores are covered by 

















Figure 8.14: Scanning electron micrograph of PU seeded with MNCs at 28 days.  After 4 
weeks in culture the scaffold was covered by cells and cellular proliferation was verified. The 
cells covered the pores and the walls of the scaffold and remained viable and healthy without 










Figure 8.15: Scanning electron micrograph of PU coated with 62.5 µg/ml of Collagen type I 
seeded with MNCs at day 0.  This micrograph showed the deposition of cells in a central 
section of the scaffold just after seeding the cells. Here again the different types of cells 

















Figure 8.16: Scanning electron micrograph of PU coated with 62.5 µg/ml of Collagen type I 
seeded with MNCs at day 14.  This central axial section of the scaffold showed how the cells 

































Figure 8.17: Scanning electron micrographs of PU coated with 62.5 µg/ml of Collagen type I 
seeded with MNCs at day 28 (a and b).  These two pictures show the walls of the scaffold 
covered by cells and expansion can be observed and compared to the micrographs at day 0 





8.4.6 Histological Examination 
CB MNCs seeded onto PU and PLGA were examined histologically with Haematoxylin 
& Eosin (H&E) staining; this type of staining is a very widely used stain in medical 
diagnosis. The staining methods involved the application of a basic dye that colours the 
basophilic structures (haematoxylin) in blue-purple colour and an alcohol-based acidic dye 
(eosin) which colours eosinophilic structures in bright pink. The eosinophilic structures are 
generally formed by the intracellular and extracellular proteins. In this investigation, H&E 
staining was used to study protein coverage of the scaffold. A homogeneous coverage of the 
protein coating and cellular distribution was apparent in both polymers (Figure 8.18-8.21). In 
the middle layer of the scaffold constructs, cells and ECM proteins were observed, together 
with the protein used for coating. Healthy looking cells can be distinguished, surrounded by 
abundant ECM proteins that most likely derived from the initial protein coating of the 
polymer. Intense pink stains show the collagen and the ECM proteins secreted by the MNCs 


















Figure 8.18: H & E stain of PLGA seeded with MNCs after 2 days of seeding.  The cells and 
the proteins can be seen in this picture. The eosin stained the secreted proteins and the 
haematoxylin the cells. The cells can be observed although hardly any protein was stained. 
 
 Due to the difficulty in cutting the scaffolds, and specially PLGA in thin sections of less 
than 5 µm, the slides were of 8-10 µm thick; thus the microscopic pictures are not well 









Figure 8.19: H & E stain of PLGA seeded with MNCs after 28 days. Protein secretion and 












Figure 8.20: H & E stain of PU coated with 62.5 µg/ml of Collagen type I seeded with 
MNCs after 28 days. Cells, protein coated collagen and secreted ECM proteins were detected 











Figure 8.21: H & E stain of PU seeded with MNCs after 28 days.  PU seeded after 28 d also 
showed protein secretion by the cells and the central section proves the fact that the cells 





Flowcytometry was used to assess the dynamics of different cell populations during the 
culture. Flowcytometry uses the principles of light scattering, light excitation, and emission 
of flourochrome molecules to generate specific-multi parameter data from the cells. The 
cultured cells were analysed for phenotypic expression of surface proteins specific for 
subpopulations of hematopoietic cells. Extracting the cells from the scaffolds was a complex 
procedure and numerous methods were tested prior the centrifugation approach was 
introduced, making it possible to remove enough cells for the assays but surely not all the 
cells in the scaffold. Due to the impossibility to predict the results, the three initial antibodies: 
CD38, CD45 and CD71 were used, but further studies using additional antibodies would 
cover all the differentiated types of cells in the hematopoietic system and need to be further 
investigated. The three antibodies used were selected depending on the type of antigen they 
recognised; below there is a list of the types of cells they identify. 
 CD45: This antibody recognises the human CD45 antigen; it is present on all human 
cells of hematopoietic origin, except erythrocytes, platelets, and their precursor cells. 
 CD38: it recognises the CD38 glycoprotein. It is found on the surface of the majority 
of hematopoietic cells, prevalently during early differentiation and activation 
processes; also on terminally differentiated B cells. 
 CD71: recognises the transferrin receptor, essential for iron transport into 
proliferating cells. CD71 is expressed on marrow stromal cells form bone marrow, on 
activated T and B lymphocytes, macrophages, and all
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expressed on resting lymphocytes. CD71 is also expressed on erythroid progenitors in 
cord blood but it is lost as theses differentiate into more mature cells.  
 
During the expansion period, the cellular composition of the culture changed; in the case 
of PLGA the flowcytometry data showed an increase in the number CD38+/CD45+ indicating 
a prevail of a more immature population of cells; the number of cells CD38+/CD71+ also 
increased over time, indicating a population of cells also formed by more mature cell types 
from the erythroid lineage. In the case of PU there seem to be a difference in maturation 
between the uncoated scaffold and the coated with collagen type I scaffold. After 14 d in 
culture cells matured faster in the case of PU coated with collagen type I, showing a smaller 
number of cells CD45+. When studying the cells at 28 d in culture, the results were alike in 
the two types of PU tested. The number of cells expressing the mature cell marker CD71 that 



















Figure 8.22: Flowcytometry graphs at day 0.  PMT2 corresponds to CD45 expression; PMT3 
corresponds to CD71 expression and PMT5 corresponds to CD38 expression. 
The data can be summarised as follows:  
Table 8.2: Flow data at day 0. The table shows the percentage of cells of each type found in 
CB MNCs before the cells were seeded onto the scaffolds. 
 CD45 CD71 CD38 
Day 0 0.65% 33.43% 17.07% 
 








Figure 8.23: Flowcytometry graphs of the CD45 isotype control. 















































































































Figure 8.25: Flowcytometry graphs of the CD38 isotype control. 
  
 PLGA was seeded with CB MNCs and the results were evaluated by flowcytometry after 
14 and 28 days. Figures 8.26 and 8.27 show the flowcytometry data obtained after 2 weeks, 





































































































Figure 8.26: Flowcytometry graphs of PLGA at day 14.  PMT2 corresponds to CD45 









Figure 8.27: Flow cytometry graphs of PLGA at day 28.  PMT2 corresponds to CD45 
expression; PMT3 corresponds to CD71 expression and PMT5 corresponds to CD38 
expression. 
  
 The numbers of CD45 increased over time; there was also an increase in the number of 
CD71 indicating maturation towards the erythroid lineage whereas the number of CD38 that 
account for the early differentiated cells decreased.  
 













































































































Figure 8.28: Flowcytometry graphs of PU at day 14.  PMT2 corresponds to CD45 











Figure 8.29: Flowcytometry graphs of PU at day 28.  PMT2 corresponds to CD45 
expression; PMT3 corresponds to CD71 expression and PMT5 corresponds to CD38 
expression. 
 




































































































 PU and PU coated with collagen and seeded with CB MNCs were also analysed using 
flowcytometry. Figure 8.28 and 8.29 present the results of PU uncoated and the change in 
cell population over time. Similarly as when using PLGA, MNCs when seeded on PU 
uncoated showed an increase in numbers of CD45 over time, while a decrease in the number 
of CD38.  This demonstrates the differentiation of the cells towards a more mature 
population. 
 Figures 8.30 and 8.31 show the flowcytometry data obtained when seeding the CB MNCs 






Figure 8.30: Flowcytometry graphs of PU coated with collagen type I at day 14.  PMT2 
corresponds to CD45 expression; PMT3 corresponds to CD71 expression and PMT5 


































































Figure 8.31: Flowcytometry graphs of PU coated with collagen type I at day 28.  PMT2 
corresponds to CD45 expression; PMT3 corresponds to CD71 expression and PMT5 
corresponds to CD38 expression. 
 
Over time, the cells maturated towards the erythroid lineage, and the response to this type 
of scaffold was similar than in the other two cases: PLGA and PU, but when using PU coated 
with collagen there was a higher increase in the number of CD45 and also a higher decrease 
in the number of CD71. 
 The numerical data of the flowcytometry results obtained for the three scaffolds tested is 

























































Table 8.3: Flowcytometry numerical data of CB MNCs seeded onto the three scaffolds. The 
table shows percentage of cells of each type found in CB MNCs at day 14 and 28.  
 PLGA PU PU coated 62 µg/ml 
 CD45 CD71 CD38 CD45 CD71 CD38 CD45 CD71 CD38 
Day 
14 
0.44% 24.47% 50.89% 1.2% 29.12% 54.94% 0.9% 34.23% 61.87% 
Day 
28 




CB MNCs cells have not yet been able to be expanded by researchers ex vivo without the 
addition of exogenous cytokines. Hence, the role of a 3-D structure that mimicked the bone 
marrow where HSC reside was investigated, and CB MNCs expanded. By studying 2-D and 
3-D growths and comparing the results, it was discovered that the 3-D structure facilitated the 
ex vivo expansion of CB MNCs without any external support. These cells formed their own 
microenvironment, which is different than the one previously created by researchers that 
included the addition of exogenous cytokines. 
Highly porous scaffolds were fabricated from PLGA and PU and provided an ideal 
system for three-dimensional CB MNC culture; these 3-D systems were optimised by coating 
the polymers with ECM proteins. In previous studies (Chapter 6 and 7) the role of two 
proteins: collagen and fibronectin using different concentrations was studied and it was 
concluded that the combination of PU coated with 62.5µg/ml was best to the support the 3-D 
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growth of the AML cells studied. As AML are leukemic hematopoietic stem cells and CB 
contains hematopoietic stem cells, it was hypothesised that the same scaffolds could be used 
to expand this other type of non-leukemic stem cells. The use of this structure as a system to 
culture CB MNCs was a novel approach to solve the difficulty to grow CB MNC ex vivo 
without the addition of expensive growth factors and has not been studied previously by other 
groups. The two polymers chosen in this study were selected due to the high-quality results 
obtained in the previous studies using leukemic stem cells, and because were highly porous, 
biocompatible and FDA approved.  In this study, PU showed a higher number of 
metabolically active cells than PLGA when seeded with CB MNCs. These results can be 
compared to the ones obtained previously when using AML cell lines where PU overall also 
showed better results. That could be explained by the differences in the porosity (PLGA= 
90.1% and PU= 85.6%) and specific pore volume (PLGA= 11.763 cm3/g and PU= 
12.310cm3/g) of the two polymers which affects cellular adhesion, viability, ingrowth, 
distribution, and formation of an ECM. The higher the porosity the greater the cellular 
growth response 175. In this case, PU has similar porosity than PLGA but the pore size varies. 
PU has homogenously sized pores; on the contrary PLGA is formed by a mixture of micro 
(≤50 µm) and macropores (≤300µm). Only PLGA macropores are capable to fit CB MNCs 
cells that have a varying size of 2-20µm depending on the cell type.  
As mentioned in the previous chapter, hydrophobicity also had an effect in the 
differences in metabolically active cells (MTS) of the synthetic polymers 177 and due to the 
fact that PLGA is more hydrophobic than PU, for this reason this tended to unfavourably 
influence cell and tissue during the initial stage of contact 178. The cells adhere and grow 
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better on hydrophilic scaffolds than in hydrophobic surfaces 179,180; thus it is natural that PU 
seeded with CB MNCs showed higher number of metabolically active cells than PLGA. In 
the case of PU coated with collagen, which showed the best results, it can be explained as a 
result of the role that ECM-containing scaffolds in cellular culture which has been 
demonstrated in a number of studies 188-190. The results of the present study supported the 
importance of the proper microenvironment for CB MNC culture. The collagen coated 
scaffolds had a cell seeding efficiency of greater than 70% in the case of PLGA, and 85% in 
the case of PU. The highest seeding efficiency was reached when using PU coated with 
collagen type I; collagen is known to accelerate cell adhesion faster than any other ECM 
proteins 190 which  explained why 24 h after cell seeding the collagen coated scaffolds 
showed an improved efficiency. 
Cellular expansion was measured using the MTS assay and corroborated and compared 
with DNA quantification; both results proved cellular expansion, one in the form of increased 
absorbance and the other related to cell number respectively. It can be appreciated that the 
first few days in culture the cells did not expand, and after 14 d they commenced a rapid 
expansion. That can be because hematopoietic cells are quiescent initially with low metabolic 
activity observed. The metabolic activity then increases and that may be caused by both, 
stromal growth and progenitor proliferation. After a period of 28 d, the CB MNCs expanded 
at different rates depending on the scaffold used. Preclinical studies of CB expansion in 2-D 
using cytokines: SCF, G-CSF and megakaryocyte growth and development factor (MGDF) 
for 10 days had a mean of 73-fold expansion of GM-CSF 236,237; that is compared to the 
maximum expansion obtained of 53-fold MNC after 28 days in PU collagen coated using 
both methods: MTS and DNA quantification; but with the difference that in our investigation 
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there were no additional cytokines. PU uncoated showed a 45-fold increase in absorbance 
and 20-fold expansion in cell number after 4 weeks; PLGA had the slowest expansion being 
7-fold when using DNA quantification and 12-fold increase in cellular activity when using 
the MTS assay. It is difficult to compare absorbance values with cell number, however the 
data was used to confirm the hypothesis that CB MNCs were expanded ex vivo without 
addition of cytokines. Viability variance between PLGA and PU could be explained by the 
different physical properties of the scaffolds. It was very challenging to extract the cells from 
the scaffolds to perform the assays, and several centrifugation steps were needed. As PLGA 
is a rigid polymer and can not bend, the handling process could have caused the lower 
viability. PU on the other hand is a very flexible, sponge-like scaffold and therefore would 
not be affected as much in the centrifugation steps. 
The expansion in number is linked with the production of stromal cells and growth 
factors. Using scanning electron micrographs taken, and comparing the data with the 
Haematoxylin & Eosin immunostaining, it can be supposed that there is stroma formation 
and growth factor secretion as the cells would not be able to expand in numbers if there 
weren’t. The SEM pictures showed an increasing number of cells in the pores that populate 
the scaffold as time progresses. The H & E sections proved that there was collagen secretion 
apart from the one present in the coated scaffolds. The slides with no collagen added before 
seeding showed a collagen formation in the scaffold. One of the challenges of the study was 
extracting the cells out from the scaffold; that was needed for flowcytometry analysis used to 
determine the differentiation pattern of the cells, and colony forming unit (CFU) assays. Up 
to now, it has been impossible to remove all the cells from the scaffolds but with a series of 
centrifugation steps some cells were extracted to carry out the assays. The studies performed 
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on the differentiation pattern of the cells lead to the conclusion that the CB MNCs seeded 
onto the scaffolds were differentiating towards plasma and erythroid lineage cells. CFUs 
showed an increment in the number of Burst-Forming Unit-Erythroid (BFU-E) over time 
when using PU as the scaffold, and a decrease in the number of CFU-GM. The data is in 
concordance with the flowcytometry results were, when using PU, the expression of CD71 
which accounts for cells differentiating towards the erythroid lineage, increased with time.  In 
the case of PLGA, the number of colonies did not change over time which is also contrasted 
with the flowcytometry results were the population of cells did not vary over time. The 
number of Colony-Forming Unit-Granulocyte, Macrophages is higher than BFU-E and 
Colony-Forming Unit, Granulocyte, Erythrocyte, Macrophage, Megakaryocyte (CFU-




In summary, the expansion of primitive CB MNCs was investigated not only because it is 
important to obtain optimal numbers for transplantation, but because the generation and 
transplantation of more lineage-committed hematopoietic progenitors is important to 
abrogate chemotherapy-induced pancytopenia. The MNCs were expanded ex vivo without the 
addition of cytokines; even if previous studies were able to support MNC expansion by 
adding amounts of cytokines that do not correspond to the measure in vivo in this case were 
growth-factor free. A 3-D structure made of polymeric scaffolds that recreated the 
microenvironment where the cells produced stroma and their own growth factors in the 
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quantities that they do normally in vivo was investigated. As a result expansion was achieved 
and the hypothesis was proven. Although there are some interrogates related to the different 
cellular differentiation depending on the scaffold, and there are multiple reasons why that 
happened, that will be subjected to another investigation. Overall, the cells differentiated 






















9.1 OVERALL CONCLUSIONS 
 The main goal in this thesis was to develop an ex-vivo 3-D model of AML. In order 
to do so, synthetic polymers were fabricated, characterised, optimised and selected. Overall 
conclusions as a result of the efforts toward this goal are summarised in the following 
sections. 
 
9.1.1 Summary of Contributions 
The possibility of mimicking the bone marrow structure seemed as an ideal solution to 
overcome the problem of culturing AML cells ex vivo. By using a three dimensional 
configuration that resembled the in vivo bone marrow, the same environment was developed  
and leukemic stem cells expanded for long periods of time; they were investigated in their 
natural environment without the addition of external growth factors. The validation of the 
three dimensional model was done by using cord blood mononuclear cells due to the fact that 
it is an alternative source of HSCs and it is easy to collect. The ex vivo expansion of cord 
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blood represented a possibility to improve the applicability and the outcome of a transplant. 
The hypothesis was that by providing a 3-D environment in the form of a scaffold it will 
facilitate the expansion of the cells in its native state (the same that it was previously assumed 
for the AML cell lines). The hypothesis was proven and the cells expanded without the 
addition of cytokines, although further studies about the differentiation patters of the cells are 
still required and need further investigation. 
The research commenced by testing six scaffolds initially chosen for the study which 
were produced in our laboratory and compared with two commercially available scaffolds 
made of similar materials. The scaffolds were tested and the selection of the two most 
suitable for AML cell line expansion was carried out. Afterwards, the polymeric scaffolds 
were optimised by protein coating the surface using two very important and common ECM 
proteins: collagen and fibronectin. The cell seeding of the protein coated scaffolds showed an 
enhanced affinity in comparison with the uncoated scaffolds. Protein was incorporated after a 
series of centrifugation steps and it resulted in better cell spreading and proliferation. 
Although the seeding efficiency was higher when using the uncoated scaffolds, overall and 
after the long term studies, the coating did improve cellular expansion. The low seeding 
efficiency which was measured 24 hours after seeding was probably caused by the acidic pH 
of the collagen solution. 
 Overall, it can be concluded that the scaffold that supported hematopoiesis ex vivo as its 
best was the scaffold made from PU and coated with 62.5 µg/ml of collagen type I. 
Nevertheless, even though collagen coating aided cellular expansion, further investigations 
are required about different and more efficient methods of coating. Protein absorption should 
 180 
 
also be quantified and the design of a perfusing system where the collagen could be 
circulated through the sample should be examined as well.  
9.1.2 Future Work 
 
9.1.2.1 Primary Leukemic Cells 
 The expansion of primary leukemic cells using the optimal scaffold selected in this thesis 
will be investigated once ethical permit has been approved. The primary leukemic cells will 
be obtained from patients undergoing bone marrow aspirates for diagnostic purposes at North 
West London Hospitals NHS Trust, and other participating Trusts, and will be cultured in 
three dimensions using the polymeric scaffold; the results will be compared with that of 
cultures using conventional 2-D methods. The 3-D cultures of these primary leukemic stem 
cells could be assessed for their structure, phenotype, and gene expression, and the growth 
environment could be analysed using scanning electron microscopy and serial paraffin thin-
sections could be immunostained for the vascular and ECM components. A virtual 3-D 
model shall be produced whereby the spatial distribution of the vasculature, ECM, and 
cellular constituents will be determined and compared with that of the original bone marrow 
trephines from the patients. The cells could be phenotyped by flowcytometry for blast-
specific markers, based on the original phenotype at diagnosis. Gene expression and 
cytogenetic studies (specific to the leukemic subtypes) possibly will be carried out on the 





9.1.2.2 Protein Adsorption 
 There have been many studies focused on protein coating of polymeric surfaces to 
improve cellular affinity, and collagen type I has been the molecule mostly used in these 
cases. The problem of measuring protein adsorption remains still uncertain; it is believed that 
there are several interactions needed in order for the protein to be adsorbed onto the solid 
surface and that the polymeric scaffold surface chemistry affects the adsorption of the 
proteins; furthermore the amount of protein adsorbed by the scaffold correlates with the 
number of surface attached cells. A number of techniques can be used for this matter such as: 
Immuno-fluorescent assay or the quartz Crystal Microbalance Dissipation Monitoring 
(QCM-D) 238 and should be used to characterise the amount of protein adsorbed by the 
scaffold. 
9.1.2.3 Serum Free Media 
 The use of a serum free media allows the standarisation of the cell culture conditions by 
avoiding the use of undefined and highly variable serum products derived from humans or 
animals and should be examined as part of the future work. Serum provides adhesion factors 
such as fibronectin, vitronectin and a mixture of soluble growth factors but the high 
variability in the biological properties of the different serum batches makes difficult the 
process standarisation. Therefore depending on the composition of the serum which still 
remains uncertain, the results can vary. In this thesis serum was used as recommended by the 
leukemic cells lines provider (ATCC®), and in the case of the cord blood serum was used in 
the quantity of 30% of the culture media. Further investigations were carried out using a 
reduced amount of serum: 10% and no serum at all and the results can be viewed in Appendix 
D. However the findings from the serum-free experiments were not positive and the cells did 
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not expand after 4 days. The use of a serum replacement media to culture HSCs seems like 
the next step to explore. The serum replacement media will be used in the same way as the 
serum containing media and the results could be compared. If the results are positive and the 
cells expand in numbers and we are able to maintain the cell population, this will be a 
breakthrough in science and the future applications of this investigation further expanded.  
It has also been proposed as another investigation, the use of a perfusion bioreactor using 
hollow-fibers and polymeric scaffolds to expand CB MNCs. By combining PU and the 
hollow fibers and providing a perfused nutrient delivery, the results could be improved. 
Cellular proliferation, colony forming units, types of cell present, viability, protein absorption 
and cellular distribution are some of the assays that will be performed for this research. 
Preliminary studies have been carried out and some results have been obtained; after initial 
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Protein Coating Study 
 
 
Appendix B provides SEM micrographs of PLGA and PU protein coated with 
collagen type I examined at different cut sections. The micrographs were taken in order to 
examine the homogenous coating obtained by several steps of centrifugation.  The first SEM 
images show the control scaffolds with no coating; the following pictures show how the 
surface changed with the coating. Some of the pores were blocked with the protein but that 
was resolved by centrifuging the scaffolds with PBS after the coating. 
 
























Figure B.1 SEMs of PLGA studied at different magnifications and coated with collagen type I. 
 




 As it can bee seen from the micrographs, protein penetration is achieved throughout the 
scaffold. Middle sections of the scaffolds were examined compared with the control scaffolds 
(that is those uncoated). The problem of pore blocking was resolved by including and 



















































































Figure D.1. Cellular Proliferation of CB MNCs seeded onto PLGA, PU, and PU collagen 




















































Figure D.2. Cellular Proliferation of CB MNCs seeded onto PLGA, PU, and PU collagen 





























































Figure E.1: MTS solution penetration. Cell seeded scaffolds were incubated with the MTS 
solution; the purple stain is the soluble formazan which is proportional to the number of 
metabolically active cells. As it can be observed, the formazan was present throughout the 
scaffold and had a homogeneous dispersion. 
 
 
 
